Apollo Endosurgery (APEN) 10-K 24 Mar 17 2016 FY Annual report Financial data

Document and Entity Information

Document and Entity Information - USD ($)	12 Months Ended
	Dec. 31, 2016	Feb. 28, 2017	Jun. 30, 2016
Document and Entity Information [Abstract]
Entity Registrant Name	APOLLO ENDOSURGERY, INC.
Entity Central Index Key	1,251,769
Document Type	10-K
Document Period End Date	Dec. 31, 2016
Amendment Flag	false
Current Fiscal Year End Date	--12-31
Entity Well-known Seasoned Issuer	No
Entity Voluntary Filers	No
Entity Current Reporting Status	Yes
Entity Filer Category	Smaller Reporting Company
Entity Public Float			$ 938,669
Entity Common Stock, Shares Outstanding		10,695,711
Document Fiscal Year Focus	2,016
Document Fiscal Period Focus	FY

Consolidated Balance Sheets

Consolidated Balance Sheets - USD ($) $ in Thousands	Dec. 31, 2016	Dec. 31, 2015
Current assets:
Cash and cash equivalents	$ 19,111	$ 21,715
Accounts receivable, net	10,509	10,498
Inventory, net	12,163	12,793
Prepaid expenses and other current assets	1,838	2,081
Total current assets	43,621	47,087
Restricted cash	930	871
Property and equipment, net	6,889	7,972
Goodwill	6,828	184
Intangible assets, net	43,315	48,987
Other assets	541	87
Total assets	102,124	105,188
Current liabilities:
Accounts payable	5,145	4,684
Accrued expenses	6,630	6,546
Payable to related parties	8,505	5,074
Contingent consideration	0	5,000
Total current liabilities	20,280	21,304
Warrant liability	0	2,912
Convertible notes	0	20,498
Long-term debt	39,427	49,305
Total liabilities	59,707	94,019
Commitments and contingencies
Redeemable preferred stock	0	144,937
Stockholders' equity/ (deficit):
Common stock; $0.001 par value; 100,000,000 shares authorized; 10,688,992 and 755,606 shares issued and outstanding at December 31, 2016 and 2015, respectively	11	1
Additional paid-in capital	190,664	(25,215)
Accumulated other comprehensive income	1,471	8
Accumulated deficit	(149,729)	(108,562)
Total stockholders' equity (deficit)	42,417	(133,768)
Total liabilities, redeemable preferred stock and stockholders' equity (deficit)	102,124	105,188
Redeemable Convertible Series A Preferred Stock [Member]
Current liabilities:
Redeemable preferred stock	0	19,301
Redeemable Convertible Series B Preferred Stock [Member]
Current liabilities:
Redeemable preferred stock	0	72,390
Redeemable Convertible Series C Preferred Stock [Member]
Current liabilities:
Redeemable preferred stock	$ 0	$ 53,246

Consolidated Balance Sheets (Pa

Consolidated Balance Sheets (Parenthetical) - USD ($) $ in Thousands	Dec. 31, 2016	Dec. 31, 2015
Common stock, par value (USD per share)	$ 0.001	$ 0.001
Common stock, shares authorized	100,000,000	100,000,000
Common stock, shares issued	10,688,992	755,606
Common stock, shares outstanding	10,688,992	755,606
Redeemable Convertible Series A Preferred Stock [Member]
Redeemable preferred stock, par value (USD per share)	$ 0.0001	$ 0.0001
Redeemable preferred stock, shares authorized	0	10,006,345
Redeemable preferred stock, shares issued	0	9,588,891
Redeemable preferred stock, shares outstanding	0	9,588,891
Redeemable preferred stock, liquidation preference	$ 0	$ 19,482
Redeemable Convertible Series B Preferred Stock [Member]
Redeemable preferred stock, par value (USD per share)	$ 0.0001	$ 0.0001
Redeemable preferred stock, shares authorized	0	45,431,126
Redeemable preferred stock, shares issued	0	45,406,582
Redeemable preferred stock, shares outstanding	0	45,406,582
Redeemable preferred stock, liquidation preference	$ 0	$ 73,620
Redeemable Convertible Series C Preferred Stock [Member]
Redeemable preferred stock, par value (USD per share)	$ 0.0001	$ 0.0001
Redeemable preferred stock, shares authorized	0	52,137,271
Redeemable preferred stock, shares issued	0	37,617,334
Redeemable preferred stock, shares outstanding	0	37,617,334
Redeemable preferred stock, liquidation preference	$ 0	$ 53,527

Consolidated Statements of Oper

Consolidated Statements of Operations and Comprehensive Loss - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2016	Dec. 31, 2015
Income Statement [Abstract]
Revenues	$ 64,868	$ 67,790
Cost of sales	25,255	20,510
Gross margin	39,613	47,280
Operating expenses:
Sales and marketing	31,751	36,167
General and administrative	13,625	11,412
Research and development	7,805	9,558
Amortization of intangible assets	7,193	6,826
Total operating expenses	60,374	63,963
Loss from operations	(20,761)	(16,683)
Other expenses:
Interest expense, net	18,168	10,036
Other expense	1,851	663
Net loss before income taxes	(40,780)	(27,382)
Income tax expense	387	49
Net loss	(41,167)	(27,431)
Current dividends on convertible preferred stock	0	(8,951)
Net loss attributable to common stockholders	(41,167)	(36,382)
Other comprehensive income:
Foreign currency translation	1,463	26
Comprehensive loss	$ (39,704)	$ (27,405)
Net loss per share, basic and diluted (USD per share)	$ (105.69)	$ (151.90)
Shares used in computing net loss per share, basic and diluted (shares)	389,501	239,509

Consolidated Statements of Chan

Consolidated Statements of Changes in Redeemable Preferred Stock and Stockholders’ Equity/(Deficit) - USD ($) $ in Thousands	Total	Warrant [Member]	Convertible Debt [Member]	Redeemable Convertible Series A Preferred Stock [Member]	Redeemable Convertible Series B Preferred Stock [Member]	Redeemable Convertible Series C Preferred Stock [Member]	Common Stock [Member]	Common Stock [Member]Warrant [Member]	Common Stock [Member]Convertible Debt [Member]	Additional Paid-in Capital [Member]	Additional Paid-in Capital [Member]Warrant [Member]	Additional Paid-in Capital [Member]Convertible Debt [Member]	Additional Paid-in Capital [Member]Redeemable Convertible Series A Preferred Stock [Member]	Additional Paid-in Capital [Member]Redeemable Convertible Series B Preferred Stock [Member]	Additional Paid-in Capital [Member]Redeemable Convertible Series C Preferred Stock [Member]	Accumulated Other Comprehensive Income (Loss) [Member]	Accumulated Deficit [Member]
Redeemable preferred stock, beginning balance (shares) at Dec. 31, 2014				9,588,891	45,431,125	49,897,462
Redeemable preferred stock, beginning balance at Dec. 31, 2014				$ 18,363	$ 67,985	$ 65,976
Redeemable Convertible Preferred Stock:
Accretion of dividends				938	$ 4,442	$ 4,577
Conversion of preferred stock, shares					(24,543)	(12,280,128)
Conversion of preferred stock	$ 0				$ (37)	$ (17,307)
Redeemable preferred stock, ending balance at Dec. 31, 2015	144,937			$ 19,301	$ 72,390	$ 53,246
Redeemable preferred stock, ending balance (shares) at Dec. 31, 2015				9,588,891	45,406,582	37,617,334
Beginning balance, shares at Dec. 31, 2014							626,605
Beginning balance at Dec. 31, 2014							$ 1			$ (36,522)						$ (18)	$ (81,131)
Redeemable convertible preferred stock and stockholders' equity, beginning balance at Dec. 31, 2014	34,654
Stockholders' Equity:
Exercise of common stock options, shares							58,232
Exercise of common stock options	123									123
Beneficial conversion feature associated with issuance of convertible notes	3,325									3,325
Accretion of dividends				$ 0	$ 0	$ 0							$ (938)	$ (4,442)	$ (4,577)
Convertible securities, shares							70,769
Convertible securities	0									17,344
Stock based compensation	472									472
Foreign currency translation	26															26
Net loss	(27,431)																(27,431)
Redeemable convertible preferred stock and stockholders' equity, ending balance at Dec. 31, 2015	11,169
Ending balance at Dec. 31, 2015	$ (133,768)						$ 1			(25,215)						8	(108,562)
Ending balance, shares at Dec. 31, 2015	755,606						755,606
Redeemable Convertible Preferred Stock:
Accretion of dividends				$ 940	$ 4,433	$ 3,667
Conversion of preferred stock, shares				(9,588,891)	(45,406,582)	(37,617,334)
Conversion of preferred stock	$ (1,286)			$ (11,530)	$ (54,241)	$ (45,699)
Common stock issued for preferred stock dividends				(8,711)	(22,582)	(11,214)
Redeemable preferred stock, ending balance at Dec. 31, 2016	0			$ 0	$ 0	$ 0
Redeemable preferred stock, ending balance (shares) at Dec. 31, 2016				0	0	0
Stockholders' Equity:
Exercise of common stock options, shares							22,964
Exercise of common stock options	53									53
Beneficial conversion feature associated with issuance of convertible notes			$ 8,678
Accretion of dividends				$ 0	$ 0	$ 0							$ (940)	$ (4,433)	$ (3,667)
Convertible securities, shares			1,269,900				5,326,500	294,438	1,269,900
Convertible securities	0		$ 24,005				$ 6		$ 1	111,464		$ 24,004
Stock based compensation	381									381
Foreign currency translation	1,463															1,463
Net loss	(41,167)																(41,167)
Issuance of common stock, shares							1,019,441
Issuance of common stock	29,000						$ 1			28,999
Common stock issued for preferred stock dividends, shares							2,000,143
Common stock issued for preferred stock dividends	0						$ 2			42,505
Business combination with Lpath, Inc.	7,087									7,087
Reclassification of warrant liability to equity	1,286									1,286
Conversion of common and preferred stock warrants into common stock		$ 462									$ 462
Redeemable convertible preferred stock and stockholders' equity, ending balance at Dec. 31, 2016	42,417
Ending balance at Dec. 31, 2016	$ 42,417						$ 11			$ 190,664						$ 1,471	$ (149,729)
Ending balance, shares at Dec. 31, 2016	10,688,992						10,688,992

Consolidated Statements of Cash

Consolidated Statements of Cash Flows - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2016	Dec. 31, 2015
Cash flows from operating activities:
Net loss	$ (41,167)	$ (27,431)
Adjustments to reconcile net loss to net cash used in operating activities:
Depreciation and amortization	9,092	8,060
Amortization of deferred financing costs	425	886
Non-cash interest expense	13,317	4,560
Change in fair value of warrant liability	(1,163)	(49)
Provision for doubtful accounts receivable	331	387
Change in inventory reserve	3,750	(54)
Stock based compensation	381	472
Foreign exchange on short-term intercompany loans	1,332	522
Changes in operating assets and liabilities:
Accounts receivable	(426)	1,268
Due from related party	0	107
Inventory	(3,054)	(6,352)
Prepaid expenses and other assets	327	(342)
Accounts payable and accrued expenses	523	512
Payable to related party	3,431	1,449
Net cash used in operating activities	(12,901)	(16,005)
Cash flows from investing activities:
Purchases of property and equipment	(1,028)	(4,763)
Purchase of intangibles and other assets	(1,337)	(2,019)
Acquisitions, net of cash acquired	200	(144)
Net cash used in investing activities	(2,165)	(6,926)
Cash flows from financing activities:
Proceeds from exercise of stock options	53	123
Proceeds from long-term debt	0	50,000
Proceeds from the issuance of convertible notes	0	22,166
Proceeds from issuance of common stock	29,000	0
Payments of deferred financing costs	(216)	(1,088)
Payment of debt	(11,220)	(37,717)
Payment of contingent consideration	(5,000)	0
Net cash provided by financing activities	12,617	33,484
Effect of exchange rate changes on cash	(96)	(216)
Net increase (decrease) in cash, cash equivalents and restricted cash	(2,545)	10,337
Cash, cash equivalents and restricted cash at beginning of year	22,586	12,249
Cash, cash equivalents and restricted cash at end of year	20,041	22,586
Supplemental disclosure of cash flow information:
Cash paid for interest	5,791	4,965
Cash paid for income taxes	318	49
Supplemental disclosure of non-cash investing and financing activity:
Conversion of convertible notes	8,678	3,325
Reclassification of warrant liability to equity	1,286	0
Warrants issued with long-term debt	0	1,951
Accretion of dividends on preferred stock	9,040	9,957
Forfeiture of dividends upon conversion of preferred stock into common stock	0	(2,304)
Warrant [Member]
Supplemental disclosure of non-cash investing and financing activity:
Conversion into common stock	462	0
Common Stock [Member]
Supplemental disclosure of non-cash investing and financing activity:
Conversion of convertible notes	24,005	0
Preferred Stock [Member]
Supplemental disclosure of non-cash investing and financing activity:
Conversion into common stock	$ 153,977	$ 0

Organization and Business Descr

Organization and Business Description	12 Months Ended
	Dec. 31, 2016
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Organization and Business Description	Organization and Business Description Apollo Endosurgery, Inc. is a Delaware corporation with both domestic and foreign wholly-owned subsidiaries. Throughout these Notes "Apollo" and the "Company" refer to Apollo Endosurgery, Inc. and its consolidated subsidiaries. Apollo is a medical technology company primarily focused on the design, development, and commercialization of innovative medical devices that can be used for the treatment of obesity. The Company's core products include the Orbera® intra-gastric balloon system, the OverStitch ™ endoscopic suturing system and Lap-Band® adjustable gastric banding system. All devices are regulated by the United States Food and Drug Administration (the "FDA") or an equivalent regulatory body outside the United States. The Company's products are sold throughout the world with principal markets in the United States of America, Europe, Australia, Brazil and Canada. The Company also has a manufacturing facility located in Costa Rica. On December 29, 2016 , Apollo completed its business combination with Lpath, Inc. ("Lpath"), a publicly held company, in accordance with the terms of the Agreement and Plan of Merger and Reorganization (the "Merger Agreement"), dated September 8, 2016 (the "Merger"). Under the terms of the Merger Agreement, each share of Apollo common stock was converted into Lpath common stock at an exchange rate of approximately 0.3163 per Apollo share ("Exchange Ratio") and the $0.0001 par value of Apollo common stock was adjusted to the Lpath $0.001 par value. Immediately following the Merger, the Company effected a reverse stock split at a ratio of one new share for every five and one-half shares of its common stock outstanding (the "1:5.5 Reverse Stock Split"). No fractional shares were issued and instead, stockholders received cash in the amount they would have been entitled to receive. The accompanying financial statements and notes to the consolidated financial statements give retroactive effect to the common stock conversion ratio and reverse stock split for all periods presented, including common stock warrants. Following the Merger, Lpath was renamed "Apollo Endosurgery, Inc." and began trading on The NASDAQ Global Market under the symbol "APEN." Prior to the Merger, Lpath was traded on The NASDAQ Capital Market under the symbol "LPTN."

Significant Accounting Policies

Significant Accounting Policies	12 Months Ended
	Dec. 31, 2016
Accounting Policies [Abstract]
Significant Accounting Policies	Significant Accounting Policies (a) Principles of Consolidation The consolidated financial statements include the accounts of the Company and all of its wholly-owned subsidiaries. All significant intercompany accounts and transactions have been eliminated. (b) Use of Estimates The preparation of consolidated financial statements in conformity with accounting principles generally accepted in the United States of America requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the consolidated financial statements and the reported amounts of revenues and expenses during the reporting periods. Actual results are likely to differ from those estimates, and such differences may be material to the consolidated financial statements. Significant items subject to such estimates and assumptions include intangibles and long-lived assets, stock compensation, deferred tax asset valuation, accounts receivable, inventory and warrant liability. (c) Cash and Cash Equivalents The Company considers all highly liquid investments with a remaining maturity at date of purchase of three months or less to be cash equivalents. (d) Restricted Cash The Company entered into irrevocable letters of credit with three banks to secure obligations under lease agreements and performance based obligations. These letters of credit total $930 and $871 and are recorded in restricted cash on the balance sheet as of December 31, 2016 and 2015 , respectively. (e) Accounts Receivable The Company generally extends credit to certain customers without requiring collateral. The Company provides an allowance for doubtful accounts based on management's evaluation of the collectability of accounts receivable. Accounts receivable are written off when it is determined amounts are uncollectible. The recorded allowance for doubtful accounts was $479 and $630 as of December 31, 2016 and 2015 , respectively. Accounts receivable of $482 and $141 were written off during the years ended December 31, 2016 and 2015 , respectively. (f) Inventory Inventory is stated at the lower of cost or market, net of any allowances. Charges for obsolete inventory are based on specific identification of obsolete inventory items and an analysis of inventory items approaching expiration date. We record estimated obsolescence charges to cost of sales. The Company's inventories are stated using the weighted average cost approach, which approximates actual costs. (g) Fair Value Measurements The carrying amounts of the Company's financial instruments, which primarily include cash and cash equivalents, accounts receivable, accounts payable and accrued expenses, approximate their fair values due to their short maturities. The fair value of the Company's long-term debt is estimated by management to approximate $40,500 at December 31, 2016. At December 31, 2015, the carrying value of the Company’s debt approximated fair value based on the borrowing rates available to the Company at that time. Management's estimates are based on comparisons of the characteristics of the Company's obligations, comparable ranges of interest rates on recently issued debt, and maturity. Such valuation inputs are considered a Level 3 measurement in the fair value valuation hierarchy. The accounting guidance defines fair value, establishes a consistent framework for measuring fair value and expands disclosure for each major asset and liability category measured at fair value on either a recurring or nonrecurring basis. Fair value is defined as an exit price, representing the amount that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants. As such, fair value is a market-based measurement that should be determined based on assumptions that market participants would use in pricing an asset or liability. As a basis for considering such assumptions, the accounting guidance establishes a three-tier fair value hierarchy, which prioritizes the inputs used in measuring fair value as follows: Level 1: Observable inputs such as quoted prices in active markets; Level 2: Inputs, other than the quoted prices in active markets, that are observable either directly or indirectly; and Level 3: Unobservable inputs in which there is little or no market data, which require the reporting entity to develop its own assumptions. The Company issued preferred stock and common stock warrants in connection with the senior-secured credit facility (see note (10)(a)) and convertible notes to a consortium of lenders (see note (10)(b)). As discussed in notes 10 and 11, these warrants were converted to common stock, or in the case of the common stock warrants in connection with the senior-secured credit facility, were reissued and reclassified as equity. Prior to the Merger, these warrants had "down-round" price protection and were recorded as a warrant liability and re-measured on the Company's reporting date at fair value. The fair value of the warrants, classified within the Level 3 designation, was determined using the Black-Scholes option pricing model and was affected by changes in inputs to that model including our stock price, expected stock price volatility, the contractual term, and the risk-free interest rate. Year Ended December 31, 2016 2015 Carrying Level 3 Carrying Level 3 Warrants classified as a liability $ — $ — $ 2,912 $ 2,912 (h) Property and Equipment Property and equipment are carried at cost less accumulated depreciation. Depreciation is computed using the straight-line method over the estimated useful lives of the related assets, except for leasehold improvements, which are depreciated straight-line over the shorter of the estimated useful life or the life of the lease. Major renewals and betterments are capitalized. Validation costs (including materials and labor) that are required to bring the machinery to working condition are capitalized. Expenditures for repairs and maintenance and minor replacements are charged to expense as incurred. (i) Business Combinations Assets acquired and liabilities assumed as part of a business acquisition are recorded at their estimated fair value at the date of acquisition. The excess of purchase price over the fair value of assets acquired and liabilities assumed is recorded as goodwill. Determining fair value of identifiable assets, particularly intangibles, and liabilities acquired also requires management to make estimates, which are based on all available information and, in some cases, assumptions with respect to the timing and amount of future revenue and expenses associated with an asset. (j) Goodwill and Other Intangible Assets Goodwill is not amortized but is tested annually for impairment or more frequently if impairment indicators exist. The Company adopted accounting guidance related to annual and interim goodwill impairment tests which allows the Company to first assess qualitative factors before performing a quantitative assessment of the fair value of a reporting unit. If it is determined on the basis of qualitative factors that the fair value of the reporting unit is more likely than not less than the carrying amount, a quantitative impairment test is required. The Company's evaluation of goodwill completed on December 31, 2016 and 2015 resulted in no impairment losses. Definite-lived intangible assets consist of customer relationships, product technology, trade names, patents and trademarks and capitalized software which are amortized over their estimated useful lives. Costs to extend the lives of and renew patents and trademarks are capitalized when incurred. (k) Valuation of Long-Lived Assets Long-lived assets, including definite-lived intangible assets, are monitored and reviewed for impairment whenever events or changes in circumstances indicate that the carrying amount of any such asset may not be recoverable. The determination of recoverability is based on an estimate of undiscounted cash flows expected to result from the use of an asset and its eventual disposition. The estimate of undiscounted cash flows is based upon, among other things, certain assumptions about expected future operating performance. The Company's estimates of undiscounted cash flows may differ from actual cash flows. If the sum of the undiscounted cash flows is less than the carrying value of the asset, an impairment charge is recognized, measured as the amount by which the carrying value exceeds the fair value of the asset. No impairment losses were recorded during the years December 31, 2016 and 2015 . (l) Revenue Recognition The Company's principal source of revenue is from the sale of its products. Revenue is recognized when evidence of an arrangement exists, fees are fixed or determinable, collection of the fees is reasonably assured, and delivery or customer acceptance of the product has occurred and no other significant obligations remain. Generally, these conditions are met under the Company's agreements with most customers upon product shipment. The Company accounts for taxes collected from customers and remitted to governmental authorities on a net basis. Accordingly, such amounts are excluded from revenues. Prior to the transition of the international commercial operations (refer to note 3(c)), the Company recognized license fee revenue paid by Allergan on a net basis. Customers generally have the right to return products purchased from the Company for up to three months from the date of product shipment or exchange products within six months. At the end of each period end, the Company determines the extent to which its revenues need to be reduced to account for expected returns and exchanges and a reserve is recorded against revenue recognized. Amounts billed to customers related to shipping and handling are included in revenues. Shipping and handling costs related to revenue producing activities are included in cost of goods sold. (m) Research and Development Research and development costs are expensed as incurred. (n) Stock-based Compensation Plans The Company recognizes compensation costs for all stock-based awards based upon each award's estimated fair value as determined on the date of grant. The Company utilizes the Black-Scholes option-pricing model to determine the fair value of stock option awards. The Black-Scholes option-pricing model requires management to make various assumptions, including valuing the Company's common stock which was done by an independent valuation firm using a blend of an income approach, market approach and cost approach before the Company became public on December 29, 2016. Compensation cost is recognized on a straight-line basis over the respective vesting period of the award, net of an estimated forfeiture rate. Adjustments for actual forfeitures are made in the period which they occur. (o) Advertising The Company expenses advertising costs as incurred. The Company incurred approximately $3,484 and $2,319 in advertising costs during the years ended December 31, 2016 and 2015 , respectively. (p) Income Taxes The Company accounts for deferred income taxes using the asset and liability method. Under this method, deferred income taxes arise from temporary differences between the tax basis of assets and liabilities and their reported amounts in the financial statements, which will result in taxable or deductible amounts in the future. Temporary differences are then measured using the enacted tax rates and laws. Valuation allowances are established, when necessary, to reduce deferred tax assets to the amount that is more-likely than-not to be realized. Determining the appropriate amount of valuation allowance requires management to exercise judgment about future operations. In the ordinary course of business, there are many transactions for which the ultimate tax outcome is uncertain. The Company regularly assesses uncertain tax positions in each of the tax jurisdictions in which it has operations and accounts for the related consolidated financial statement implications. The amount of unrecognized tax benefits is adjusted when information becomes available or when an event occurs indicating a change is appropriate. The Company includes interest and penalties related to its uncertain tax positions as part of income tax expense. (q) Medical Device Excise Tax Effective as of January 1, 2013, the Patient Protection and Affordable Care Act, as amended by the Health Care and Education Affordability Reconciliation Act, imposed a medical device excise tax (MDET) of 2.3% on any entity that manufactures or imports certain medical devices offered for sale in the United States. The Company accounts for the MDET as a component of sales and marketing expense within operating expense and recognized approximately zero and $754 during the years ended December 31, 2016 and 2015 , respectively. In December 2015, the medical device tax was suspended for two years and thus no tax was imposed during 2016 or will be imposed during 2017 . (r) Foreign Currency The Company is exposed to foreign currency exchange risk as foreign subsidiaries generally operate and utilize functional currencies in local currencies other than the U.S. Dollar, which is the Company's reporting currency. The Company translates their foreign assets and liabilities at exchange rates in effect at the balance sheet dates, and the revenues and expenses using average rates during the year. The resulting foreign currency translation adjustments are recorded as a separate component of accumulated other comprehensive income in the accompanying consolidated balance sheets. We do not hedge foreign currency translation risk in the net assets and income we report from these sources. Exchange rate fluctuations on short-term intercompany loans are included in other expense in the consolidated statement of operations and comprehensive loss. (s) Recent Accounting Pronouncements In May 2014, the Financial Accounting Standards Board ("FASB") issued Accounting Standards Update ("ASU") 2014-09, Revenue from Contracts with Customers ("ASU 2014-09"), which requires an entity to recognize the amount of revenue to which it expects to be entitled for the transfer of promised goods or services to customers. ASU 2014-09 replaces most existing revenue recognition guidance in GAAP. In July 2015, the FASB approved a one-year deferral of this standard, with a revised effective date for annual and interim reporting in fiscal years beginning after December 15, 2017. In March 2016 and April 2016, the FASB issued ASU 2016-08, Principal versus Agent Considerations (Reporting Revenue Gross versus Net ) and ASU 2016-10, Identifying Performance Obligations and Licensing , respectively. ASU 2014-09 permits the use of either the retrospective or modified retrospective (cumulative effect) transition method. The Company has not yet completed its final review of the impact of this guidance, although the Company does not anticipate a material impact on its revenue recognition practices. The Company continues to review this guidance, potential disclosures and the Company’s method of adoption to complete its evaluation of the impact on its consolidated financial statements. In addition, the Company continues to monitor additional changes, modifications, clarifications or interpretations being undertaken by the FASB, which may impact the Company’s current conclusions. Apollo has adopted the provisions of ASU 2014-15, Disclosure of Uncertainties about an Entity's Ability to Continue as a Going Concern ("ASU 2014-15"). This ASU requires management to evaluate, for each annual and interim reporting period, whether there are conditions and events, considered in the aggregate, that raise substantial doubt about an entity's ability to continue as a going concern within one year after the date the financial statements are issued or are available to be issued. If substantial doubt is raised, additional disclosures around management's plan to alleviate these doubts are required. The adoption of ASU 2014-15 resulted in no material impact on the Company's consolidated financial statements. Apollo has adopted the provisions of ASU 2015-03, Simplifying the Presentation of Debt Issuance Costs . This update requires that debt issuance costs be presented in the balance sheet as a reduction of the carrying value of the debt instead of being classified as a deferred charge. As retrospective application is required by this standard, December 31, 2016 and 2015 have been adjusted with no material impact, respectively. In July 2015, the FASB, issued ASU 2015-11, Simplifying the Measurement of Inventory ("ASU 2015-11"), which simplifies the subsequent measurement of inventory by requiring inventory to be measured at the lower of cost and net realizable value. Net realizable value is the estimated selling price in the ordinary course of business, less reasonably predictable costs of completion, disposal and transportation. ASU 2015-11 will be effective for the Company on January 1, 2017. The Company does not expect the adoption of ASU 2015-11 will have a material impact on its consolidated financial statements. In November 2015, the FASB issued ASU 2015-17, Balance Sheet Classification of Deferred Taxes ("ASU 2015-17") which requires that all deferred tax assets and liabilities, along with any related valuation allowance, be classified as noncurrent on the balance sheet. ASU 2015-17 will be effective for the Company on January 1, 2017. The adoption of ASU 2015-17 will not have a material impact on the presentation of the Company's consolidated balance sheet. In February 2016, the FASB issued ASU 2016-02, Leases ("ASU 2016-02") which requires a lessee to recognize assets and liabilities for leases with a maximum possible term of more than 12 months. A lessee would recognize a liability to make lease payments (the lease liability) and a right-of-use asset representing its right to use the leased asset (the underlying asset) for the lease term which will require companies to recognize most leases on the balance sheet, thereby increasing reported assets and liabilities. Extensive quantitative and qualitative disclosures, including significant judgments made by management, will be required. ASU 2016-02 requires adoption using a modified retrospective transition with application of the guidance at the beginning of the earliest comparative period presented. ASU 2016-02 will be effective for the Company on January 1, 2019. Early adoption is permitted. The Company is evaluating the effect that ASU 2016-02 will have on its consolidated financial statements. In March 2016, the FASB issued ASU 2016-09, Improvements to Employee Share-Based Payment Accounting ("ASU 2016-09"), which contains guidance on accounting for certain aspects of share-based payments to employees. ASU 2016-09 requires excess tax benefits and tax deficiencies to be recorded in the income statement when the awards vest or are settled. Furthermore, cash flows related to excess tax benefits will no longer be separately classified as a financing activity apart from other income tax cash flows. ASU 2016-09 also allows companies to repurchase more of an employee's shares for tax withholding purposes without triggering liability accounting, clarifying that all cash payments made on an employee's behalf for withheld shares should be presented as a financing activity in the consolidated statements of cash flows and provides an accounting policy election to account for forfeitures as they occur. ASU 2016-09 will be effective for the Company on January 1, 2017. The Company does not expect the adoption of ASU 2016-09 to have a material impact on its consolidated financial statements. The Company adopted the provisions of ASU 2016-15, Statement of Cash Flows: Classification of Certain Cash Receipts and Cash Payments ("ASU 2016-15") which addresses questions about the presentation and classification of certain cash receipts and payments in the statement of cash flows, including debt prepayment costs. The adoption of ASU 2016-15 resulted in no material impact to the Company's consolidated financial statements for the periods presented. The Company adopted the provisions of ASU 2016-18, Statement of Cash Flows: Restricted Cash ("ASU 2016-18") which clarifies the classification and presentation of changes in restricted cash on the statement of cash flows. With the adoption of ASU 2016-18 restricted cash is now included in the statement of cash flows. In January 2017, the FASB issued ASU 2017-01, Business Combinations: Clarifying the Definition of a Business ("ASU 2017-01") which changes the definition of a business. If substantially all of the fair value of the gross assets acquired is concentrated in a single identifiable asset or group of similar identifiable assets, then the acquisition is not a business. ASU 2017-01 requires a business to include at least one substantive process. ASU 2017-01 will be effective for the Company on January 1, 2018. Early adoption is permitted. The effect of ASU 2017-01 on the Company's consolidated financial statements will be dependent on any future acquisitions. In January 2017, the FASB issued ASU 2017-04, Intangibles - Goodwill and Other: Simplifying the Test for Goodwill Impairment (“ASU 2017-04”) to simplify the accounting for goodwill impairment. The guidance removes Step 2 of the goodwill impairment test, which requires a hypothetical purchase price allocation. A goodwill impairment will now be the amount by which a reporting unit’s carrying value exceeds its fair value, not to exceed the carrying amount of goodwill. Entities will continue to have the option to perform a qualitative assessment to determine if a quantitative impairment test is necessary. ASU 2017-04 will be effective for the Company for annual and interim reporting in fiscal years beginning after December 15, 2019. Early adoption is permitted. The Company does not expect the adoption of ASU 2017-04 to have a material impact on its consolidated financial statements.

Acquisitions

Acquisitions	12 Months Ended
	Dec. 31, 2016
Business Combinations [Abstract]
Acquisitions	Acquisitions (a) Lpath On December 29, 2016 , the Company completed the Merger with Lpath as discussed in note 1. The Merger was accounted for as a reverse merger under the acquisition method of accounting whereby Apollo was considered to have acquired Lpath for financial reporting purposes because, immediately upon completion of the Merger, Apollo stockholders held a majority of the voting interest of the combined company. Immediately after the Merger, holders of Apollo and Lpath common stock, warrants and options owned approximately 95.9% and 4.1% of the fully-diluted common stock of the Company, respectively. In addition, transaction costs associated with the Lpath merger of $3,640 are included in general and administrative expense. The total purchase price for Lpath was $7,087 based on the fair value of the Lpath stock price and market capitalization and was allocated as follows: December 29, 2016 Cash $ 200 Other assets 519 Assumed liabilities (276 ) Fair value of net assets 443 Goodwill 6,644 Total purchase consideration $ 7,087 The preliminary allocation of the Lpath Merger purchase price resulted in $6,644 of goodwill. The final allocation of the purchase price is dependent on the value, if any, resulting from the final disposition of the Lpath IP and may differ from the amounts included in these financial statements. The Company expects to complete the final allocation as soon as practical but no later than one year from the acquisition date. Management does not expect adjustments, if any, resulting from changes to the purchase price allocation, to have a material effect on the Company’s financial position or results of operations. The following summary pro forma condensed consolidated financial information reflects the Merger with Lpath as if it had occurred on January 1, 2015 for purposes of the statements of operations. This summary pro forma information is not necessarily representative of what the Company’s results of operations would have been had the Merger in fact occurred on January 1, 2015, and is not intended to project the Company’s results of operations for any future period. Pro forma condensed consolidated financial information for 2016 and 2015 (unaudited): Year Ended December 31, 2016 2015 Pro form combined revenues $ 65,163 $ 69,390 Pro forma combined net loss $ (33,269 ) $ (34,521 ) Pro forma combined earnings per share $ (3.11 ) $ (4.23 ) Pro forma combined net loss includes adjustments to remove transactions costs of $5,140 for the year ended December 31, 2016 because they will not have a continuing impact on operations, and a reduction in historical interest expense of $13,258 and $2,920 for the year ended December 31, 2016 and 2015, respectively, due to the conversion of the convertible notes and warrants. (b) Starhealth On June 3, 2015, the Company entered into a purchase agreement to acquire the shares of Starhealth Distribuidora ("Starhealth") in Brazil for $144 . Starhealth included certain business licenses needed for conducting business in Brazil. As a result of the transaction, the Company recorded $144 of intangible assets in the form of business licenses which were amortized over one year . (c) Allergan On December 2, 2013, the Company entered into an asset purchase agreement to acquire the bariatric assets of Allergan, Inc. ("Allergan") which was accounted for as a taxable asset acquisition for tax purposes. Pursuant to the purchase agreement, the Company paid $62,460 and agreed to pay future contingent consideration, and the seller purchased $15,000 of Series C preferred stock for cash. Additionally, certain contingent payments were due if (1) U.S. Lap-Band revenues exceeded certain thresholds in the initial three years following the acquisition date, or (2) Orbera Post-Market Approval from the FDA was received in the United States prior to December 2, 2015. A contingent consideration payment of $5,000 was paid on May 26, 2016 for obtaining Orbera post market approval. The Lap-Band and Orbera products were manufactured by Allergan until transition to the Company on December 2, 2015. A manufacturing fee of 115% of the cost to manufacture the Lap-Band and Orbera product was charged to the Company. The Company recorded inventory purchases of $7,667 and $13,555 related to the manufacturing agreement during 2016 and 2015, respectively. Allergan distributed the Lap-Band and Orbera products outside of the United States and continued to employ all employees that support those sales until transition to the Company, which occurred in Canada, Australia and all direct selling markets in Europe prior to December 2, 2014, with Latin America transition following on December 2, 2015. Distribution relationships and contracts that related to sales of the Lap-Band and Orbera products outside of the United States transitioned to the Company prior to December 2, 2015. For the rights to distribute the Company's Lap-Band and Orbera products, the Company was paid a license fee and recognized $2,624 of licensing fee revenue related to this distribution agreement during 2015. Worldwide technical research and development product support for the Lap-Band and Orbera products was provided until transition to the Company on December 2, 2015. The Company recognized in research and development $1,240 of related expense under this transition agreement during 2015.

Concentrations

Concentrations	12 Months Ended
	Dec. 31, 2016
Risks and Uncertainties [Abstract]
Concentrations	Concentrations Consolidated financial instruments that potentially subject the Company to a concentration of credit risk principally consist of cash and cash equivalents and accounts receivable. At December 31, 2016 , the Company's cash and cash equivalents and restricted cash are held in deposit accounts at three different banks totaling $20,041 . The Company has not experienced any losses in such accounts, and management does not believe the Company is exposed to any significant credit risk. Management further believes that the concentration of credit risk in the Company's accounts receivable is substantially mitigated by the Company's evaluation process, relatively short collection terms, and the high level of creditworthiness of its customers. The Company continually evaluates the status of each of its customers, but generally requires no collateral. The Company had no customers that comprised a concentration greater than 10% of the Company's total accounts receivable as of December 31, 2016 or 2015 , or revenues for the years ended December 31, 2016 and 2015 .

Inventory

Inventory	12 Months Ended
	Dec. 31, 2016
Inventory Disclosure [Abstract]
Inventory	Inventory Inventory consists of the following as of December 31: 2016 2015 Raw materials $ 5,031 $ — Work in progress 346 — Finished goods 10,520 13,021 Less inventory reserve (3,734 ) (228 ) Total inventory, net $ 12,163 $ 12,793 The Company commenced its manufacturing operations in Costa Rica in June 2016. The Company recorded an inventory impairment charge of $3,750 for the year ended December 31, 2016 consisting of $1,226 of estimated obsolescence charges for raw materials transferred in June 2016 in accordance with the Allergan manufacturing agreement and $2,524 related to expiring finished goods products.

Property and Equipment

Property and Equipment	12 Months Ended
	Dec. 31, 2016
Property, Plant and Equipment [Abstract]
Property and Equipment	Property and Equipment Property and equipment consists of the following as of December 31: Depreciable 2016 2015 Equipment 5 years $ 4,949 $ 2,070 Furniture, fixtures and tooling 4 - 8 years 3,533 3,429 Computer hardware 3 - 5 years 1,057 1,063 Leasehold improvements 3 - 5 years 1,149 919 Construction in process 605 4,365 11,293 11,846 Less accumulated depreciation (4,404 ) (3,874 ) Property and equipment, net $ 6,889 $ 7,972 The Company recorded depreciation expense of $1,862 and $1,225 for the years ended December 31, 2016 and 2015 , respectively. There were no impairment charges for the years ended December 31, 2016 or 2015 . The Company capitalized interest of $109 and $269 for the years ended December 31, 2016 and 2015 , respectively related to our manufacturing facility in Costa Rica. The Company disposed of $1,270 of property and equipment which was fully depreciated as of December 31, 2016 and no longer being utilized by the Company.

Goodwill and Other Intangible A

Goodwill and Other Intangible Assets	12 Months Ended
	Dec. 31, 2016
Goodwill and Intangible Assets Disclosure [Abstract]
Goodwill and Other Intangible Assets	Goodwill and Other Intangible Assets The following table reflects the changes in goodwill for the years ended December 31, 2016 and 2015 : December 31, 2014 $ 184 December 31, 2015 $ 184 Goodwill associated with Lpath, Inc. merger 6,644 December 31, 2016 $ 6,828 Other intangible assets consist of the following as of December 31: Useful Life 2016 2015 Customer relationships 9 years $ 30,300 $ 30,300 Lap-Band technology 10 years 15,500 15,500 Orbera technology 12 years 4,600 4,600 Trade names 10 years 7,900 7,900 Patents and trademarks 5 years 4,178 2,907 Other 1 - 4 years 1,796 1,460 64,274 62,667 Less accumulated amortization (20,959 ) (13,680 ) $ 43,315 $ 48,987 Amortization expense related to the above intangible assets was $7,230 and $6,835 during 2016 and 2015 , respectively. Additionally, we capitalized $1,271 and $1,256 related to the extension and renewal of our patents and trademarks during 2016 and 2015, respectively. Amortization for the next five years is as follows: 2017 $ 7,360 2018 7,233 2019 6,932 2020 6,508 2021 6,209 Thereafter 9,073 Total $ 43,315

Accrued Expenses

Accrued Expenses	12 Months Ended
	Dec. 31, 2016
Payables and Accruals [Abstract]
Accrued Expenses	Accrued Expenses Accrued expenses consist of the following as of December 31: 2016 2015 Accrued compensation and travel $ 3,040 $ 3,447 Accrued professional service fees 1,521 608 Accrued returns and rebates 366 453 Accrued insurance, property and sales taxes 256 618 Accrued interest 186 155 Deferred rent 152 173 Deferred revenue 88 — Other 1,021 1,092 Total accrued expenses $ 6,630 $ 6,546

Convertible Notes

Convertible Notes	12 Months Ended
	Dec. 31, 2016
Debt Disclosure [Abstract]
Convertible Notes	Convertible Notes From July through November 2015, the Company entered into various convertible note purchase agreements which resulted in gross proceeds of $22,166 . The notes accrued interest at a rate of 6% per annum which was added to the outstanding amount until conversion. Interest accrued for the notes was $1,326 and $513 for the years ended December 31, 2016 and 2015, respectively. The notes had an optional voluntary conversion feature in which the holder could convert the notes into the Company's Series C preferred stock at a rate of 115% times the sum of the outstanding principal and unpaid accrued interest at the issuance price of $1.2223 per share on or after July 29, 2016. Alternatively, the notes converted into common stock or preferred stock equal to a range of 115% to 150% of the sum of outstanding principal and interest upon certain contingent qualifying events such as a public offering or liquidation event. The intrinsic value of this beneficial conversion feature was $3,325 upon issuance of the notes and was recorded as additional paid-in capital on the statement of stockholders' deficit and as a debt discount which accreted to interest expense through the first optional conversion date of July 29, 2016. Interest expense included discount amortization of $2,073 and $1,252 for the years ended December 31, 2016 and 2015, respectively. The debt discount was fully amortized at July 29, 2016. Immediately prior to the Merger, all of the convertible notes and accrued interest thereon were converted into 1,269,900 shares of common stock on December 29, 2016 at 150% of the sum of the outstanding principal and interest and a conversion price of $1.6361 . The additional intrinsic value of the contingent beneficial conversion feature of $8,678 was included in interest expense in 2016 and was recorded as additional paid in capital upon conversion of the notes. 2015 Convertible notes $ 22,166 Interest accrued 513 22,679 Discount (2,073 ) Deferred financing costs (108 ) Convertible notes $ 20,498 Long-Term Debt Long-term debt consists of the following as of December 31: 2016 2015 Senior secured credit facility $ 39,000 $ 50,000 Payment-in-kind interest 2,046 1,679 Long-term debt 41,046 51,679 Discount on long-term debt (952 ) (1,606 ) Deferred financing costs (667 ) (768 ) Long-term debt $ 39,427 $ 49,305 (a) Senior Secured Credit Facility On February 27, 2015, the Company entered into a senior secured credit facility (the "Credit Facility") with a lender to borrow $50,000 which is payable in a lump sum on February 27, 2020. The Credit Facility is secured by all of the Company's assets and has priority over all other debt. The Credit Facility bears interest at 10.5% per annum. In the first year, 7% cash interest was paid quarterly and 3.5% of payment-in-kind which was added to the outstanding debt. After March 15, 2016, 10.5% of interest became payable in cash on a quarterly basis. An additional 2% of the outstanding amount will be due at end of the loan term. The Company is accruing this additional payment-in-kind interest as interest expense using the effective interest rate method. The Company used $39,500 of these proceeds in 2015 to pay off the outstanding long-term debt to the consortium of lenders discussed below. On December 29, 2016 , the Company paid $11,000 of the outstanding balance of the Credit Facility and prepayment and payment-in-kind interest of $770 , included in interest expense. Unamortized deferred financing costs of $127 and unamortized discount of $269 were written off in December 2016 in connection with this payment. The Credit Facility includes covenants and terms that place certain restrictions on the Company's ability to incur additional debt, incur additional liens, make investments, effect mergers, declare or pay dividends, sell assets, engage in transactions with affiliates, or make capital expenditures. The Credit Facility also includes financial covenants including minimum consolidated quarterly revenue, consolidated debt to revenue ratio and minimum cash balances and provides certain limited cure provisions in the event these requirements are not met. During 2015 the Company was required to hold a minimum of $5,000 of cash. The Company amended the Credit Facility in March 2016 and amended its debt covenants, which resulted in the Company being subject to lower minimum quarterly revenue requirements, a lower maximum debt-to-revenue ratio and a requirement to hold a minimum of $10,000 of cash. During the second quarter of 2016 the Company was not in compliance with the debt-to-revenue covenant and received a waiver from the lender. On October 10, 2016 , the Company entered into a Fourth Amendment to the Credit Agreement in connection with the Merger Agreement. The amendment amended and restated certain clauses within the debt agreement to conform to public company standards as well as adjusted the financial covenants as follows: • Minimum revenue requirement increased quarterly from $15,700 to $25,000 from September 30, 2016 through February 27, 2020; • Minimum debt to revenue ratio decreased quarterly from 0.80 to 0.40 from September 30, 2016 through February 27, 2020; and • Minimum cash requirement reduced to $8,000 . As of December 31, 2016 , the Company was in compliance with the financial covenants after utilization of the available cure provision rights. In connection with the Credit Facility, the Company granted a warrant to purchase a total of 163,915 shares of common stock with an exercise price of $21.29 per share. The warrant is exercisable at the option of the holder at any time and expires on February 7, 2022. The fair value of the warrant issued was $1,951 using the Black-Scholes model and was recorded as a warrant liability on the balance sheet and as a debt discount which is being amortized to interest expense over the term of the related note payable using the interest method. The warrant liability was reduced by $641 and $24 for the years ended December 31, 2016 and 2015, respectively in order to reflect fair value with an offsetting credit to interest expense. In connection with the Fourth Amendment, the Company issued the lender a new warrant to purchase 163,915 shares of common stock with an exercise price of $21.29 per share. This warrant replaced the warrant issued in connection with the Credit Facility for the same number of shares and exercise price per share and removed the anti-dilution provisions included in the prior warrant. This warrant is classified as equity. (b) Note with a Consortium of Lenders In November 2013, the Company entered into a credit agreement with a consortium of lenders to borrow $50,000 . Amounts outstanding under this credit agreement beared interest at 8.25% and were collateralized by all assets of the Company. Loan commitment fees related to this transaction of $750 , plus legal fees of $241 were capitalized as other noncurrent assets and were being amortized to interest expense over the note term of 60 months using the interest method. The outstanding balance under the credit agreement was prepaid in February 2015, including prepayment penalties of $1,795 , which were included in interest expense. Unamortized deferred financing costs of $641 were written off in February 2015 when the debt was repaid. In connection with the credit agreement, the Company granted a warrant to purchase a total of 70,580 shares of Series C preferred stock with an exercise price of $21.29 per share. The warrant was exercisable at the option of the holder at any time and expired on November 30, 2020. The fair value of the warrant issued was $1,142 using the Black-Scholes model and was recorded as warrant liability on the balance sheet and as a debt discount which was amortized to interest expense over the term of the related note payable using the interest method until the debt was refinanced and unamortized discount was written off to interest expense. The Company reduced the warrant liability by $522 and $25 for the years ended December 31, 2016 and 2015 respectively to reflect fair value with an offsetting credit to interest expense. The warrant was net exercised and exchanged for 44,027 shares of common stock immediately prior to the Merger and is no longer outstanding at December 31, 2016 .

Long-Term Debt

Long-Term Debt	12 Months Ended
	Dec. 31, 2016
Debt Disclosure [Abstract]
Long-Term Debt	Convertible Notes From July through November 2015, the Company entered into various convertible note purchase agreements which resulted in gross proceeds of $22,166 . The notes accrued interest at a rate of 6% per annum which was added to the outstanding amount until conversion. Interest accrued for the notes was $1,326 and $513 for the years ended December 31, 2016 and 2015, respectively. The notes had an optional voluntary conversion feature in which the holder could convert the notes into the Company's Series C preferred stock at a rate of 115% times the sum of the outstanding principal and unpaid accrued interest at the issuance price of $1.2223 per share on or after July 29, 2016. Alternatively, the notes converted into common stock or preferred stock equal to a range of 115% to 150% of the sum of outstanding principal and interest upon certain contingent qualifying events such as a public offering or liquidation event. The intrinsic value of this beneficial conversion feature was $3,325 upon issuance of the notes and was recorded as additional paid-in capital on the statement of stockholders' deficit and as a debt discount which accreted to interest expense through the first optional conversion date of July 29, 2016. Interest expense included discount amortization of $2,073 and $1,252 for the years ended December 31, 2016 and 2015, respectively. The debt discount was fully amortized at July 29, 2016. Immediately prior to the Merger, all of the convertible notes and accrued interest thereon were converted into 1,269,900 shares of common stock on December 29, 2016 at 150% of the sum of the outstanding principal and interest and a conversion price of $1.6361 . The additional intrinsic value of the contingent beneficial conversion feature of $8,678 was included in interest expense in 2016 and was recorded as additional paid in capital upon conversion of the notes. 2015 Convertible notes $ 22,166 Interest accrued 513 22,679 Discount (2,073 ) Deferred financing costs (108 ) Convertible notes $ 20,498 Long-Term Debt Long-term debt consists of the following as of December 31: 2016 2015 Senior secured credit facility $ 39,000 $ 50,000 Payment-in-kind interest 2,046 1,679 Long-term debt 41,046 51,679 Discount on long-term debt (952 ) (1,606 ) Deferred financing costs (667 ) (768 ) Long-term debt $ 39,427 $ 49,305 (a) Senior Secured Credit Facility On February 27, 2015, the Company entered into a senior secured credit facility (the "Credit Facility") with a lender to borrow $50,000 which is payable in a lump sum on February 27, 2020. The Credit Facility is secured by all of the Company's assets and has priority over all other debt. The Credit Facility bears interest at 10.5% per annum. In the first year, 7% cash interest was paid quarterly and 3.5% of payment-in-kind which was added to the outstanding debt. After March 15, 2016, 10.5% of interest became payable in cash on a quarterly basis. An additional 2% of the outstanding amount will be due at end of the loan term. The Company is accruing this additional payment-in-kind interest as interest expense using the effective interest rate method. The Company used $39,500 of these proceeds in 2015 to pay off the outstanding long-term debt to the consortium of lenders discussed below. On December 29, 2016 , the Company paid $11,000 of the outstanding balance of the Credit Facility and prepayment and payment-in-kind interest of $770 , included in interest expense. Unamortized deferred financing costs of $127 and unamortized discount of $269 were written off in December 2016 in connection with this payment. The Credit Facility includes covenants and terms that place certain restrictions on the Company's ability to incur additional debt, incur additional liens, make investments, effect mergers, declare or pay dividends, sell assets, engage in transactions with affiliates, or make capital expenditures. The Credit Facility also includes financial covenants including minimum consolidated quarterly revenue, consolidated debt to revenue ratio and minimum cash balances and provides certain limited cure provisions in the event these requirements are not met. During 2015 the Company was required to hold a minimum of $5,000 of cash. The Company amended the Credit Facility in March 2016 and amended its debt covenants, which resulted in the Company being subject to lower minimum quarterly revenue requirements, a lower maximum debt-to-revenue ratio and a requirement to hold a minimum of $10,000 of cash. During the second quarter of 2016 the Company was not in compliance with the debt-to-revenue covenant and received a waiver from the lender. On October 10, 2016 , the Company entered into a Fourth Amendment to the Credit Agreement in connection with the Merger Agreement. The amendment amended and restated certain clauses within the debt agreement to conform to public company standards as well as adjusted the financial covenants as follows: • Minimum revenue requirement increased quarterly from $15,700 to $25,000 from September 30, 2016 through February 27, 2020; • Minimum debt to revenue ratio decreased quarterly from 0.80 to 0.40 from September 30, 2016 through February 27, 2020; and • Minimum cash requirement reduced to $8,000 . As of December 31, 2016 , the Company was in compliance with the financial covenants after utilization of the available cure provision rights. In connection with the Credit Facility, the Company granted a warrant to purchase a total of 163,915 shares of common stock with an exercise price of $21.29 per share. The warrant is exercisable at the option of the holder at any time and expires on February 7, 2022. The fair value of the warrant issued was $1,951 using the Black-Scholes model and was recorded as a warrant liability on the balance sheet and as a debt discount which is being amortized to interest expense over the term of the related note payable using the interest method. The warrant liability was reduced by $641 and $24 for the years ended December 31, 2016 and 2015, respectively in order to reflect fair value with an offsetting credit to interest expense. In connection with the Fourth Amendment, the Company issued the lender a new warrant to purchase 163,915 shares of common stock with an exercise price of $21.29 per share. This warrant replaced the warrant issued in connection with the Credit Facility for the same number of shares and exercise price per share and removed the anti-dilution provisions included in the prior warrant. This warrant is classified as equity. (b) Note with a Consortium of Lenders In November 2013, the Company entered into a credit agreement with a consortium of lenders to borrow $50,000 . Amounts outstanding under this credit agreement beared interest at 8.25% and were collateralized by all assets of the Company. Loan commitment fees related to this transaction of $750 , plus legal fees of $241 were capitalized as other noncurrent assets and were being amortized to interest expense over the note term of 60 months using the interest method. The outstanding balance under the credit agreement was prepaid in February 2015, including prepayment penalties of $1,795 , which were included in interest expense. Unamortized deferred financing costs of $641 were written off in February 2015 when the debt was repaid. In connection with the credit agreement, the Company granted a warrant to purchase a total of 70,580 shares of Series C preferred stock with an exercise price of $21.29 per share. The warrant was exercisable at the option of the holder at any time and expired on November 30, 2020. The fair value of the warrant issued was $1,142 using the Black-Scholes model and was recorded as warrant liability on the balance sheet and as a debt discount which was amortized to interest expense over the term of the related note payable using the interest method until the debt was refinanced and unamortized discount was written off to interest expense. The Company reduced the warrant liability by $522 and $25 for the years ended December 31, 2016 and 2015 respectively to reflect fair value with an offsetting credit to interest expense. The warrant was net exercised and exchanged for 44,027 shares of common stock immediately prior to the Merger and is no longer outstanding at December 31, 2016 .

Stockholders' Equity

Stockholders' Equity	12 Months Ended
	Dec. 31, 2016
Equity [Abstract]
Stockholders' Equity	Stockholders' Equity (a) Authorized Stock The Company’s amended and restated certificate of incorporation, effective upon the completion of the Merger, authorizes the Company to issue 115,000,000 shares of common and preferred stock, consisting of 100,000,000 shares of common stock with $0.001 par value and 15,000,000 shares of preferred stock with $0.001 par value. The Company has reserved common shares for issuance upon the exercise of the authorized and issued common stock options and warrants. Prior to the Merger, the Company had authorized 107,574,742 shares of preferred stock, of which 10,006,345 shares were designated as Series A convertible preferred stock ("Series A"), 45,431,126 shares are designated as Series B convertible preferred stock ("Series B") and 52,137,271 shares are designated as Series C convertible preferred stock ("Series C"). Holders of the preferred stock were entitled to receive dividends out of any assets legally available for payment of cumulative dividends at the annual rate of 8% . As of December 31, 2015 , the Company had outstanding 9,588,891 shares of Series A, 45,406,582 shares of Series B and 37,617,334 shares of Series C. (b) Merger In the Merger, the previously outstanding shares of convertible preferred stock were converted on a one -to-one basis into shares of common stock and then subject to the Exchange Ratio and 1:5.5 Reverse Stock Split, resulting in all of the outstanding shares of Series A, Series B and Series C preferred stock and the accumulated dividends of $42,507 thereon being converted into 7,326,643 shares of common stock. Following the merger, there were no shares of preferred stock outstanding. Immediately prior to the Merger, the Company issued and sold an aggregate of 1,019,441 shares of common stock for approximately $29,000 . (c) Warrants Immediately prior to the Merger, preferred stock warrants were net exercised and exchanged for 15,866 shares of common stock. Immediately prior to the Merger, common stock warrants were net exercised and exchanged for 234,545 shares of common stock. In connection with the Merger, Lpath issued warrants to purchase 40,456 shares of common stock to its financial adviser, which are currently outstanding at December 31, 2016. The warrants have an exercise price of $13.70 and expire on December 29, 2021. Additionally, Lpath had previously issued 59,537 warrants that as of December 31, 2016 were outstanding with an exercise price of $324.08 , expiring through September 2019.

Stock Option Plans

Stock Option Plans	12 Months Ended
	Dec. 31, 2016
Disclosure of Compensation Related Costs, Share-based Payments [Abstract]
Stock Option Plans	Stock Option Plans (a) Plans 2006 Plan The Company's 2006 Equity Incentive Plan (the "2006 Plan") allows that employees, consultants, and nonemployee directors of the Company may be granted incentive stock options or nonqualified stock options to purchase shares of the Company's common stock. Options to date have been granted to employees at 100% of the fair value at the date of the grant. The fair value, vesting period, and expiration dates of the options granted are determined by the Board of Directors at the time of grant. The maximum term of options granted under the 2006 Plan is 10 years from the date of grant. Options generally vest over a period of time, typically not more than 5 years . The Company also has the right of first refusal for any proposed disposition of shares under the 2006 Plan. Under certain circumstances, the Company may repurchase previously granted options or shares issued upon the exercise of a previously granted option. The 2006 Plan expired in May 2016. 2016 Plan The Company's 2016 Equity Incentive Plan (the "2016 Plan") allows that employees, consultants, and nonemployee directors of the Company may be granted incentive stock options, nonstatutory stock options, stock appreciation rights, restricted stock awards restricted stock units and other stock awards to purchase shares of the Company's common stock. Options to date have been granted to employees at 100% of the fair value at the date of the grant. The fair value, vesting period, and expiration dates of the options granted are determined by the Board of Directors at the time of grant. The maximum term of options granted under the 2016 Plan is 10 years from the date of grant. Options generally vest over a period of time, typically not more than 5 years . The Company also has the right of first refusal for any proposed disposition of shares under the 2016 Plan. Shares subject to awards granted under the 2006 Plan or 2016 Plan which expire, are repurchased, or are canceled or forfeited will again become available for issuance under the 2016 Plan. The shares available will not be reduced by awards settled in cash or by shares withheld to satisfy tax withholding obligations. Only the net number of shares issued upon the exercise of stock appreciation rights or options exercised by means of a net exercise will be deducted from the shares available under the 2016 Plan. As of December 31, 2016 , the Company has 21,319,756 shares of common stock reserved for issuance under the 2016 Plan. Lpath Plan The Lpath Amended and Restated 2005 Equity Incentive Plan (the "Lpath Plan") allows for grants of incentive stock options with exercise prices of at least 100% of the fair market value of Lpath's common stock, nonqualified options with exercise prices of at least 85% of the fair market value of the company's common stock. All stock options granted to date have a 10 year life and vest over 0 to 5 years . At December 31, 2016, Lpath optionees had 3,182 outstanding options, expiring through March 2017. (b) Stock Option Activity A summary of the stock option activity under the 2006 Plan, 2016 Plan and Lpath Plan (collectively the "Equity Plans") as of December 31, 2016 is presented below. Note that the Company did not account for the Lpath plan until the close of the Merger on December 29, 2016 and the tables below reflect Lpath information only after this date. Options Weighted Average Exercise Price Weighted Average Remaining Contractual Term Aggregate Intrinsic Value (Years) ($000's) Options outstanding, December 31, 2015 972,565 $2.96 7.6 years $— Options granted 235,414 1.99 Options exercised (22,964 ) 2.35 Options forfeited (168,368 ) 1.88 Options outstanding, December 31, 2016 1,016,647 $2.94 7.0 years $9,343 Options vested and expected to vest, December 31, 2016 1,011,863 $2.94 7.0 years $9,343 Options exercisable, December 31, 2016 548,262 $2.79 6.3 years $5,137 The fair value for options under the Equity Plans was estimated at the date of grant using the Black-Scholes option pricing model in valuing its stock awards. Prior to the Merger, the value of the Company's common stock was determined by an independent valuation firm using a blend of an income approach, market approach and cost approach. The Black-Scholes model requires estimating dividend yield, volatility, risk-free rate of return, estimated forfeitures during the service period and the expected term of the award. The expected dividend yield assumption is based on the Company’s expectation of zero future dividend payouts. The volatility assumption is based on the historical volatilities of the Company’s common stock and of comparable public companies. The risk free rate of return assumption utilizes yields on U.S. treasury zero-coupon bonds with maturity that is commensurate with the expected term for awards issued to employees and the contractual term for awards issued to non-employees. The expected term is derived using the simplified method and represents the weighted average period that the stock awards are expected to remain outstanding. The fair value of stock option grants has been estimated at the date of grant using the Black-Scholes option pricing model with the following weighted average assumptions for the years ended December 31: 2016 2015 Risk free interest rate 1.4% 1.7% Expected dividend yield —% —% Estimated volatility 57.0% 81.2% Expected life 5.5 years 6.0 years Additional information regarding options is as follows: 2016 2015 Stock compensation cost $ 381 $ 472 Weighted-average grant date fair value of options granted during the period $ 1.22 $ 2.22 Aggregate intrinsic value of options exercised during the period $ 42 $ 48 The aggregate intrinsic value in the table above represents the total pre-tax value of the options shown, calculated as the difference between the Company’s closing stock price on December 31, 2016 and the exercise prices of the options shown, multiplied by the number of in-the money options. This is the aggregate amount that would have been received by the option holders if they had all exercised their options on December 31, 2016 and sold the shares thereby received at the closing price of the Company’s stock on that date. This amount changes based on the closing price of the Company’s stock. The Company has granted 139,513 options to purchase common shares that will vest upon the Company's achievement of certain global revenue and EBITDA targets for calendar years 2016 and 2017. These performance targets are not deemed probable and thus no amounts have been recognized associated with these amounts. Unrecognized compensation expense related to unvested options was approximately $567 at December 31, 2016 , with a remaining amortization period of less than four years .

Commitments

Commitments	12 Months Ended
	Dec. 31, 2016
Commitments and Contingencies Disclosure [Abstract]
Commitments	Commitments (a) Lease Commitments The Company has entered into various lease agreements for its operating facilities in Texas and California, the manufacturing facility located in Costa Rica, and for office spaces in the United Kingdom, Australia, Italy and Brazil. The Company also has various lease agreements for equipment and vehicles. Lease expense for the years ended December 31, 2016 and 2015 was $1,120 and $930 , respectively. Certain of these leases contain scheduled rent increases which are included in lease expense and recognized using the straight-line method over the term of the leases. At December 31, 2016 , minimum rental commitments under non-cancelable operating leases payable over the next five years are as follows: 2017 $ 1,505 2018 887 2019 569 2020 481 2021 384 Thereafter — Total $ 3,826 (b) Risk Management The Company maintains various forms of insurance that the Company's management believes are adequate to reduce the exposure to these risks to an acceptable level. (c) Employment Agreements Certain executive officers are entitled to payments if they are terminated without cause or as a result of a change in control. Upon termination without cause, and not as a result of death or disability, each of such officers is entitled to receive a payment of base salary for three to twelve months following termination of employment and such officer will be entitled to continue to receive coverage under medical and dental benefit plans for three to twelve months or until such officer is covered under a separate plan from another employer. Upon a termination other than for cause or for good reason within 12 months following a change in control, each of such officers will be entitled to the same benefits as upon termination without cause and will also be entitled to certain acceleration of such officer's outstanding unvested options at the time of such termination. (d) Litigation Management believes that there are no claims or actions pending or threatened against the Company, the ultimate disposition of which would have a material impact on the Company's consolidated financial position, results of operations or cash flows. We were informed by the Department of Justice that the Company is a subject in a federal False Claims Act investigation. The government’s investigation concerns whether there has been or is a violation of the False Claims Act, 31 U.S.C. § 3729 et. seq. related to the marketing of the Lap-Band system, including the web-based physician locator provided on our website Lap-Band.com. We believe the investigation covers the period before and after our acquisition of the obesity intervention division of Allergan, Inc. in December 2013. We are cooperating fully with the investigation, but we cannot predict the outcome of the investigation or the effect of the findings of the investigation on our business, but it is possible that the foregoing matter could result in a material adverse effect on our business, reputation, results of operation and financial condition.

Defined Contribution Plan

Defined Contribution Plan	12 Months Ended
	Dec. 31, 2016
Compensation and Retirement Disclosure [Abstract]
Defined Contribution Plan	Defined Contribution Plan The Company sponsors a defined contribution plan for employees in the U.S. The cost of this plan, including employer contributions, was $553 and $555 for the years ended December 31, 2016 and 2015 respectively.

Income Taxes

Income Taxes	12 Months Ended
	Dec. 31, 2016
Income Tax Disclosure [Abstract]
Income Taxes	Income Taxes Income tax expense of $387 and $49 for the years ended December 31, 2016 and 2015, respectively is composed of foreign income taxes on earnings generated in the foreign subsidiaries. Deferred income taxes reflect the net effects of temporary differences between the carrying amounts of assets and liabilities for financial reporting purposes and the amounts used for income tax purposes. Significant components of the Company's deferred taxes at December 31 are as follows: 2016 2015 Deferred tax assets: Capitalized transaction costs $ 686 $ 742 Intangible assets 2,794 1,741 Inventory valuation 1,371 173 Research and development credit 2,796 2,522 Foreign timing differences 117 — Unremitted foreign earnings 100 — Other 1,121 1,162 Net operating loss carryforwards 44,087 35,780 53,072 42,120 Deferred tax liabilities: Depreciable assets (288 ) (230 ) (288 ) (230 ) Total net deferred tax assets 52,784 41,890 Less valuation allowance (52,784 ) (41,890 ) Net deferred tax assets (liabilities) $ — $ — The Company has established a valuation allowance equal to the total net deferred tax asset due to uncertainties regarding the realization of deferred tax assets based on the Company's lack of earnings history and potential limitations pursuant to changes in ownership under Internal Revenue Code Section 382. The valuation allowance increased by $10,894 during the year ended December 31, 2016 , primarily as a result of changes in net operating loss. As of December 31, 2016 , the Company has no unrecognized tax benefits or accrued interest or penalties associated with uncertain tax positions. The Company's provision for income taxes differs from the expected tax expense amount computed by applying the statutory federal income tax rate of 34% to income before income taxes as a result of the following: 2016 2015 Tax at U.S. statutory rate of 34% $ (13,865 ) $ (9,327 ) State taxes, net of deferred benefit (1,061 ) (628 ) Foreign tax rate differential 422 775 Foreign taxes 91 49 Permanent differences 3,942 269 Contingent purchase price — (1,625 ) Research and development tax credit (240 ) (345 ) Other 204 (18 ) Change in valuation allowance 10,894 10,899 Income tax expense $ 387 $ 49 As of December 31, 2016 , the Company had federal net operating loss carryforwards of approximately $123,335 which will expire in varying amounts beginning in 2025 if not utilized. Under the provisions of the Internal Revenue Code, certain substantial changes in the Company's ownership may result in a limitation on the amount of net operating loss carryforwards which can be used in future years. The Company had state net operating loss carryforwards of approximately $43,330 which will begin to expire in varying amounts beginning in 2019. The Company had foreign net operating losses of approximately $4,120 of which $0 have an indefinite carryforward. The remaining amount of $4,120 begin to expire in varying amounts beginning in 2020, if not utilized.

Net Loss Per Share

Net Loss Per Share	12 Months Ended
	Dec. 31, 2016
Earnings Per Share [Abstract]
Net Loss Per Share	Net Loss Per Share The basic and diluted net loss per common share presented in the consolidated statement of operations and comprehensive loss is calculated by dividing net loss attributable to common stockholders by the weighted-average number of common shares outstanding during the period, without consideration for common stock equivalents. For the purposes of determining net loss per share in 2016, the additional common shares from the Lpath merger transaction on December 29, 2016 were weighted as outstanding for two days for the year ended December 31, 2016. Net loss attributable to common stockholders in 2015 was computed by deducting current dividends on convertible preferred stock from net loss. Potentially dilutive shares, which include convertible preferred stock in 2015, warrants for the purchase of common and preferred stock, and options outstanding under the Company's equity incentive plans, are considered to be common stock equivalents and are only included in the calculation of diluted net loss per share when their effect is dilutive. Potentially dilutive securities not included in the calculation of diluted net loss per share attributable to common stockholders because to do so would be anti-dilutive are as follows (in common stock equivalent shares): Year Ended December 31 2016 2015 Preferred stock — 6,901,130 Warrants for common and preferred stock 263,856 495,144 Common stock options 1,016,647 972,565 1,280,503 8,368,839

Related Party Transactions

Related Party Transactions	12 Months Ended
	Dec. 31, 2016
Related Party Transactions [Abstract]
Related Party Transactions	Related Party Transactions Transitional services for manufacturing, distribution and technical product support were provided by Allergan (see note 3). The Company owed Allergan $1,259 and $1,205 for transitional services and $7,246 and $3,750 for purchases of inventory that are recorded in payable to related parties at December 31, 2016 and 2015 , respectively. Additionally, Allergan holds 70,580 shares of the Company's common stock as of December 31, 2016 .

Liquidity and Capital Resources

Liquidity and Capital Resources	12 Months Ended
	Dec. 31, 2016
Debt Disclosure [Abstract]
Liquidity and Capital Resources	Liquidity and Capital Resources The Company has experienced operating losses and debt covenant violations since inception and has an accumulated deficit of $149,729 as of December 31, 2016 . To date, the Company has funded its operating losses and acquisitions through private equity offerings and the issuance of debt instruments. The Company's ability to fund future operations and satisfy its ongoing debt covenant requirements will depend upon its level of future operating cash flow and its ability to access additional funding through either equity offerings, issuances of debt instruments or both. On February 27, 2015, the Company entered into a Credit Facility (see note 10(a)) which requires the Company to meet minimum revenue requirements and other covenants each quarter and provides a cure provision in the event this requirement is not met. If the Company is not able to meet its ongoing quarterly covenant requirements or utilize the remaining cure provision rights, the repayment of the Credit Facility could be accelerated at the lender's discretion. The Company believes its existing cash and cash equivalents and remaining cure provision rights will be sufficient to meet liquidity and capital requirements for a reasonable period of time.

Segment and Geographic Informat

Segment and Geographic Information	12 Months Ended
	Dec. 31, 2016
Segment Reporting [Abstract]
Segment and Geographic Information	Segment and Geographic Information Operating segments are defined as components of an enterprise for which separate financial information is available and evaluated regularly by the chief operating decision maker, or decision-making group, in deciding how to allocate resources and in assessing performance. The Company globally manages the business within one reportable segment. Segment information is consistent with how management reviews the business, makes investing and resource allocation decisions and assesses operating performance. The Company’s products are principally sold in the U.S. No other countries are individually significant. Product sales by product group and geographic market, based on the location of the customer, for the periods shown were as follows: Year Ended December 31, 2016 Year Ended December 31, 2015 U.S. OUS Total Revenue % Total Revenue U.S. OUS Total Revenue % Total Revenue Endo-bariatric $ 15,525 $ 16,382 $ 31,907 49.2 % $ 9,119 $ 8,003 $ 17,122 25.3 % Surgical 21,778 10,706 32,484 50.1 % 34,975 12,628 47,603 70.2 % Other 453 24 477 0.7 % 425 2,640 3,065 4.5 % Total revenues $ 37,756 $ 27,112 $ 64,868 100.0 % $ 44,519 $ 23,271 $ 67,790 100.0 % % Total revenue 58.2 % 41.8 % 65.7 % 34.3 % The following table represents property and equipment, net based on the physical geographic location of the asset: 2016 2015 United States $ 2,426 $ 3,028 Costa Rica 4,177 4,598 Other 268 346 Total property and equipment, net $ 6,871 $ 7,972

Subsequent Events

Subsequent Events	12 Months Ended
	Dec. 31, 2016
Subsequent Events [Abstract]
Subsequent Events	Subsequent Events On March 7, 2017, the Company entered into a Fifth Amendment to the Credit Agreement with its lender, Athyrium Opportunities II Acquisition LP ("Athyrium"), to modify the terms of its senior secured credit facility. Specifically, the Fifth Amendment (i) reduced the minimum cash balance requirement to $0 from $8,000 , (ii) reduced the minimum quarterly revenue requirement to $13,000 from $18,000 , (iii) increased the maximum debt-to-revenue ratio to 0.65 from 0.60 and (iv) required Apollo to make a principal repayment of $7,000 . The minimum quarterly revenue requirement will increase by $1,000 quarterly over the remaining term of the facility, and the maximum debt-to-revenue ratio will decline gradually each quarter, from 0.65 to 0.25 , over the remaining term of the facility.

Significant Accounting Polici27

Significant Accounting Policies (Policies)	12 Months Ended
	Dec. 31, 2016
Accounting Policies [Abstract]
Principles of Consolidation	Principles of Consolidation The consolidated financial statements include the accounts of the Company and all of its wholly-owned subsidiaries. All significant intercompany accounts and transactions have been eliminated.
Use of Estimates	Use of Estimates The preparation of consolidated financial statements in conformity with accounting principles generally accepted in the United States of America requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the consolidated financial statements and the reported amounts of revenues and expenses during the reporting periods. Actual results are likely to differ from those estimates, and such differences may be material to the consolidated financial statements. Significant items subject to such estimates and assumptions include intangibles and long-lived assets, stock compensation, deferred tax asset valuation, accounts receivable, inventory and warrant liability.
Cash and Cash Equivalents	Cash and Cash Equivalents The Company considers all highly liquid investments with a remaining maturity at date of purchase of three months or less to be cash equivalents.
Restricted Cash	Restricted Cash The Company entered into irrevocable letters of credit with three banks to secure obligations under lease agreements and performance based obligations.
Accounts Receivable	Accounts Receivable The Company generally extends credit to certain customers without requiring collateral. The Company provides an allowance for doubtful accounts based on management's evaluation of the collectability of accounts receivable. Accounts receivable are written off when it is determined amounts are uncollectible
Inventory	Inventory Inventory is stated at the lower of cost or market, net of any allowances. Charges for obsolete inventory are based on specific identification of obsolete inventory items and an analysis of inventory items approaching expiration date. We record estimated obsolescence charges to cost of sales. The Company's inventories are stated using the weighted average cost approach, which approximates actual costs.
Fair Value Measurements	Fair Value Measurements The carrying amounts of the Company's financial instruments, which primarily include cash and cash equivalents, accounts receivable, accounts payable and accrued expenses, approximate their fair values due to their short maturities. The fair value of the Company's long-term debt is estimated by management to approximate $40,500 at December 31, 2016. At December 31, 2015, the carrying value of the Company’s debt approximated fair value based on the borrowing rates available to the Company at that time. Management's estimates are based on comparisons of the characteristics of the Company's obligations, comparable ranges of interest rates on recently issued debt, and maturity. Such valuation inputs are considered a Level 3 measurement in the fair value valuation hierarchy. The accounting guidance defines fair value, establishes a consistent framework for measuring fair value and expands disclosure for each major asset and liability category measured at fair value on either a recurring or nonrecurring basis. Fair value is defined as an exit price, representing the amount that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants. As such, fair value is a market-based measurement that should be determined based on assumptions that market participants would use in pricing an asset or liability. As a basis for considering such assumptions, the accounting guidance establishes a three-tier fair value hierarchy, which prioritizes the inputs used in measuring fair value as follows: Level 1: Observable inputs such as quoted prices in active markets; Level 2: Inputs, other than the quoted prices in active markets, that are observable either directly or indirectly; and Level 3: Unobservable inputs in which there is little or no market data, which require the reporting entity to develop its own assumptions. The Company issued preferred stock and common stock warrants in connection with the senior-secured credit facility (see note (10)(a)) and convertible notes to a consortium of lenders (see note (10)(b)). As discussed in notes 10 and 11, these warrants were converted to common stock, or in the case of the common stock warrants in connection with the senior-secured credit facility, were reissued and reclassified as equity. Prior to the Merger, these warrants had "down-round" price protection and were recorded as a warrant liability and re-measured on the Company's reporting date at fair value. The fair value of the warrants, classified within the Level 3 designation, was determined using the Black-Scholes option pricing model and was affected by changes in inputs to that model including our stock price, expected stock price volatility, the contractual term, and the risk-free interest rate.
Property and Equipment	Property and Equipment Property and equipment are carried at cost less accumulated depreciation. Depreciation is computed using the straight-line method over the estimated useful lives of the related assets, except for leasehold improvements, which are depreciated straight-line over the shorter of the estimated useful life or the life of the lease. Major renewals and betterments are capitalized. Validation costs (including materials and labor) that are required to bring the machinery to working condition are capitalized. Expenditures for repairs and maintenance and minor replacements are charged to expense as incurred.
Business Combinations	Business Combinations Assets acquired and liabilities assumed as part of a business acquisition are recorded at their estimated fair value at the date of acquisition. The excess of purchase price over the fair value of assets acquired and liabilities assumed is recorded as goodwill. Determining fair value of identifiable assets, particularly intangibles, and liabilities acquired also requires management to make estimates, which are based on all available information and, in some cases, assumptions with respect to the timing and amount of future revenue and expenses associated with an asset. The Merger was accounted for as a reverse merger under the acquisition method of accounting whereby Apollo was considered to have acquired Lpath for financial reporting purposes because, immediately upon completion of the Merger, Apollo stockholders held a majority of the voting interest of the combined company.
Goodwill and Other Intangible Assets	Goodwill and Other Intangible Assets Goodwill is not amortized but is tested annually for impairment or more frequently if impairment indicators exist. The Company adopted accounting guidance related to annual and interim goodwill impairment tests which allows the Company to first assess qualitative factors before performing a quantitative assessment of the fair value of a reporting unit. If it is determined on the basis of qualitative factors that the fair value of the reporting unit is more likely than not less than the carrying amount, a quantitative impairment test is required. The Company's evaluation of goodwill completed on December 31, 2016 and 2015 resulted in no impairment losses. Definite-lived intangible assets consist of customer relationships, product technology, trade names, patents and trademarks and capitalized software which are amortized over their estimated useful lives. Costs to extend the lives of and renew patents and trademarks are capitalized when incurred.
Valuation of Long-Lived Assets	Valuation of Long-Lived Assets Long-lived assets, including definite-lived intangible assets, are monitored and reviewed for impairment whenever events or changes in circumstances indicate that the carrying amount of any such asset may not be recoverable. The determination of recoverability is based on an estimate of undiscounted cash flows expected to result from the use of an asset and its eventual disposition. The estimate of undiscounted cash flows is based upon, among other things, certain assumptions about expected future operating performance. The Company's estimates of undiscounted cash flows may differ from actual cash flows. If the sum of the undiscounted cash flows is less than the carrying value of the asset, an impairment charge is recognized, measured as the amount by which the carrying value exceeds the fair value of the asset.
Revenue Recognition	Revenue Recognition The Company's principal source of revenue is from the sale of its products. Revenue is recognized when evidence of an arrangement exists, fees are fixed or determinable, collection of the fees is reasonably assured, and delivery or customer acceptance of the product has occurred and no other significant obligations remain. Generally, these conditions are met under the Company's agreements with most customers upon product shipment. The Company accounts for taxes collected from customers and remitted to governmental authorities on a net basis. Accordingly, such amounts are excluded from revenues. Prior to the transition of the international commercial operations (refer to note 3(c)), the Company recognized license fee revenue paid by Allergan on a net basis. Customers generally have the right to return products purchased from the Company for up to three months from the date of product shipment or exchange products within six months. At the end of each period end, the Company determines the extent to which its revenues need to be reduced to account for expected returns and exchanges and a reserve is recorded against revenue recognized. Amounts billed to customers related to shipping and handling are included in revenues. Shipping and handling costs related to revenue producing activities are included in cost of goods sold.
Research and Development	Research and Development Research and development costs are expensed as incurred.
Stock-based Compensation Plans	Stock-based Compensation Plans The Company recognizes compensation costs for all stock-based awards based upon each award's estimated fair value as determined on the date of grant. The Company utilizes the Black-Scholes option-pricing model to determine the fair value of stock option awards. The Black-Scholes option-pricing model requires management to make various assumptions, including valuing the Company's common stock which was done by an independent valuation firm using a blend of an income approach, market approach and cost approach before the Company became public on December 29, 2016. Compensation cost is recognized on a straight-line basis over the respective vesting period of the award, net of an estimated forfeiture rate. Adjustments for actual forfeitures are made in the period which they occur.
Advertising	Advertising The Company expenses advertising costs as incurred.
Income Taxes	Income Taxes The Company accounts for deferred income taxes using the asset and liability method. Under this method, deferred income taxes arise from temporary differences between the tax basis of assets and liabilities and their reported amounts in the financial statements, which will result in taxable or deductible amounts in the future. Temporary differences are then measured using the enacted tax rates and laws. Valuation allowances are established, when necessary, to reduce deferred tax assets to the amount that is more-likely than-not to be realized. Determining the appropriate amount of valuation allowance requires management to exercise judgment about future operations. In the ordinary course of business, there are many transactions for which the ultimate tax outcome is uncertain. The Company regularly assesses uncertain tax positions in each of the tax jurisdictions in which it has operations and accounts for the related consolidated financial statement implications. The amount of unrecognized tax benefits is adjusted when information becomes available or when an event occurs indicating a change is appropriate. The Company includes interest and penalties related to its uncertain tax positions as part of income tax expense.
Medical Device Excise Tax	Medical Device Excise Tax Effective as of January 1, 2013, the Patient Protection and Affordable Care Act, as amended by the Health Care and Education Affordability Reconciliation Act, imposed a medical device excise tax (MDET) of 2.3% on any entity that manufactures or imports certain medical devices offered for sale in the United States. The Company accounts for the MDET as a component of sales and marketing expense within operating expense and recognized approximately zero and $754 during the years ended December 31, 2016 and 2015 , respectively. In December 2015, the medical device tax was suspended for two years and thus no tax was imposed during 2016 or will be imposed during 2017 .
Foreign Currency	Foreign Currency The Company is exposed to foreign currency exchange risk as foreign subsidiaries generally operate and utilize functional currencies in local currencies other than the U.S. Dollar, which is the Company's reporting currency. The Company translates their foreign assets and liabilities at exchange rates in effect at the balance sheet dates, and the revenues and expenses using average rates during the year. The resulting foreign currency translation adjustments are recorded as a separate component of accumulated other comprehensive income in the accompanying consolidated balance sheets. We do not hedge foreign currency translation risk in the net assets and income we report from these sources. Exchange rate fluctuations on short-term intercompany loans are included in other expense in the consolidated statement of operations and comprehensive loss.
Recent Accounting Pronouncements	Recent Accounting Pronouncements In May 2014, the Financial Accounting Standards Board ("FASB") issued Accounting Standards Update ("ASU") 2014-09, Revenue from Contracts with Customers ("ASU 2014-09"), which requires an entity to recognize the amount of revenue to which it expects to be entitled for the transfer of promised goods or services to customers. ASU 2014-09 replaces most existing revenue recognition guidance in GAAP. In July 2015, the FASB approved a one-year deferral of this standard, with a revised effective date for annual and interim reporting in fiscal years beginning after December 15, 2017. In March 2016 and April 2016, the FASB issued ASU 2016-08, Principal versus Agent Considerations (Reporting Revenue Gross versus Net ) and ASU 2016-10, Identifying Performance Obligations and Licensing , respectively. ASU 2014-09 permits the use of either the retrospective or modified retrospective (cumulative effect) transition method. The Company has not yet completed its final review of the impact of this guidance, although the Company does not anticipate a material impact on its revenue recognition practices. The Company continues to review this guidance, potential disclosures and the Company’s method of adoption to complete its evaluation of the impact on its consolidated financial statements. In addition, the Company continues to monitor additional changes, modifications, clarifications or interpretations being undertaken by the FASB, which may impact the Company’s current conclusions. Apollo has adopted the provisions of ASU 2014-15, Disclosure of Uncertainties about an Entity's Ability to Continue as a Going Concern ("ASU 2014-15"). This ASU requires management to evaluate, for each annual and interim reporting period, whether there are conditions and events, considered in the aggregate, that raise substantial doubt about an entity's ability to continue as a going concern within one year after the date the financial statements are issued or are available to be issued. If substantial doubt is raised, additional disclosures around management's plan to alleviate these doubts are required. The adoption of ASU 2014-15 resulted in no material impact on the Company's consolidated financial statements. Apollo has adopted the provisions of ASU 2015-03, Simplifying the Presentation of Debt Issuance Costs . This update requires that debt issuance costs be presented in the balance sheet as a reduction of the carrying value of the debt instead of being classified as a deferred charge. As retrospective application is required by this standard, December 31, 2016 and 2015 have been adjusted with no material impact, respectively. In July 2015, the FASB, issued ASU 2015-11, Simplifying the Measurement of Inventory ("ASU 2015-11"), which simplifies the subsequent measurement of inventory by requiring inventory to be measured at the lower of cost and net realizable value. Net realizable value is the estimated selling price in the ordinary course of business, less reasonably predictable costs of completion, disposal and transportation. ASU 2015-11 will be effective for the Company on January 1, 2017. The Company does not expect the adoption of ASU 2015-11 will have a material impact on its consolidated financial statements. In November 2015, the FASB issued ASU 2015-17, Balance Sheet Classification of Deferred Taxes ("ASU 2015-17") which requires that all deferred tax assets and liabilities, along with any related valuation allowance, be classified as noncurrent on the balance sheet. ASU 2015-17 will be effective for the Company on January 1, 2017. The adoption of ASU 2015-17 will not have a material impact on the presentation of the Company's consolidated balance sheet. In February 2016, the FASB issued ASU 2016-02, Leases ("ASU 2016-02") which requires a lessee to recognize assets and liabilities for leases with a maximum possible term of more than 12 months. A lessee would recognize a liability to make lease payments (the lease liability) and a right-of-use asset representing its right to use the leased asset (the underlying asset) for the lease term which will require companies to recognize most leases on the balance sheet, thereby increasing reported assets and liabilities. Extensive quantitative and qualitative disclosures, including significant judgments made by management, will be required. ASU 2016-02 requires adoption using a modified retrospective transition with application of the guidance at the beginning of the earliest comparative period presented. ASU 2016-02 will be effective for the Company on January 1, 2019. Early adoption is permitted. The Company is evaluating the effect that ASU 2016-02 will have on its consolidated financial statements. In March 2016, the FASB issued ASU 2016-09, Improvements to Employee Share-Based Payment Accounting ("ASU 2016-09"), which contains guidance on accounting for certain aspects of share-based payments to employees. ASU 2016-09 requires excess tax benefits and tax deficiencies to be recorded in the income statement when the awards vest or are settled. Furthermore, cash flows related to excess tax benefits will no longer be separately classified as a financing activity apart from other income tax cash flows. ASU 2016-09 also allows companies to repurchase more of an employee's shares for tax withholding purposes without triggering liability accounting, clarifying that all cash payments made on an employee's behalf for withheld shares should be presented as a financing activity in the consolidated statements of cash flows and provides an accounting policy election to account for forfeitures as they occur. ASU 2016-09 will be effective for the Company on January 1, 2017. The Company does not expect the adoption of ASU 2016-09 to have a material impact on its consolidated financial statements. The Company adopted the provisions of ASU 2016-15, Statement of Cash Flows: Classification of Certain Cash Receipts and Cash Payments ("ASU 2016-15") which addresses questions about the presentation and classification of certain cash receipts and payments in the statement of cash flows, including debt prepayment costs. The adoption of ASU 2016-15 resulted in no material impact to the Company's consolidated financial statements for the periods presented. The Company adopted the provisions of ASU 2016-18, Statement of Cash Flows: Restricted Cash ("ASU 2016-18") which clarifies the classification and presentation of changes in restricted cash on the statement of cash flows. With the adoption of ASU 2016-18 restricted cash is now included in the statement of cash flows. In January 2017, the FASB issued ASU 2017-01, Business Combinations: Clarifying the Definition of a Business ("ASU 2017-01") which changes the definition of a business. If substantially all of the fair value of the gross assets acquired is concentrated in a single identifiable asset or group of similar identifiable assets, then the acquisition is not a business. ASU 2017-01 requires a business to include at least one substantive process. ASU 2017-01 will be effective for the Company on January 1, 2018. Early adoption is permitted. The effect of ASU 2017-01 on the Company's consolidated financial statements will be dependent on any future acquisitions. In January 2017, the FASB issued ASU 2017-04, Intangibles - Goodwill and Other: Simplifying the Test for Goodwill Impairment (“ASU 2017-04”) to simplify the accounting for goodwill impairment. The guidance removes Step 2 of the goodwill impairment test, which requires a hypothetical purchase price allocation. A goodwill impairment will now be the amount by which a reporting unit’s carrying value exceeds its fair value, not to exceed the carrying amount of goodwill. Entities will continue to have the option to perform a qualitative assessment to determine if a quantitative impairment test is necessary. ASU 2017-04 will be effective for the Company for annual and interim reporting in fiscal years beginning after December 15, 2019. Early adoption is permitted. The Company does not expect the adoption of ASU 2017-04 to have a material impact on its consolidated financial statements.
Net Loss Per Share	The basic and diluted net loss per common share presented in the consolidated statement of operations and comprehensive loss is calculated by dividing net loss attributable to common stockholders by the weighted-average number of common shares outstanding during the period, without consideration for common stock equivalents. For the purposes of determining net loss per share in 2016, the additional common shares from the Lpath merger transaction on December 29, 2016 were weighted as outstanding for two days for the year ended December 31, 2016. Net loss attributable to common stockholders in 2015 was computed by deducting current dividends on convertible preferred stock from net loss. Potentially dilutive shares, which include convertible preferred stock in 2015, warrants for the purchase of common and preferred stock, and options outstanding under the Company's equity incentive plans, are considered to be common stock equivalents and are only included in the calculation of diluted net loss per share when their effect is dilutive.

Significant Accounting Polici28

Significant Accounting Policies (Tables)	12 Months Ended
	Dec. 31, 2016
Accounting Policies [Abstract]
Fair Value of Warrants	The fair value of the warrants, classified within the Level 3 designation, was determined using the Black-Scholes option pricing model and was affected by changes in inputs to that model including our stock price, expected stock price volatility, the contractual term, and the risk-free interest rate. Year Ended December 31, 2016 2015 Carrying Level 3 Carrying Level 3 Warrants classified as a liability $ — $ — $ 2,912 $ 2,912

Acquisitions (Tables)

Acquisitions (Tables)	12 Months Ended
	Dec. 31, 2016
Business Combinations [Abstract]
Schedule of Purchase Price of Lpath	The total purchase price for Lpath was $7,087 based on the fair value of the Lpath stock price and market capitalization and was allocated as follows: December 29, 2016 Cash $ 200 Other assets 519 Assumed liabilities (276 ) Fair value of net assets 443 Goodwill 6,644 Total purchase consideration $ 7,087
Schedule of Pro Forma Information	Pro forma condensed consolidated financial information for 2016 and 2015 (unaudited): Year Ended December 31, 2016 2015 Pro form combined revenues $ 65,163 $ 69,390 Pro forma combined net loss $ (33,269 ) $ (34,521 ) Pro forma combined earnings per share $ (3.11 ) $ (4.23 )

Inventory (Tables)

Inventory (Tables)	12 Months Ended
	Dec. 31, 2016
Inventory Disclosure [Abstract]
Schedule of Inventory	Inventory consists of the following as of December 31: 2016 2015 Raw materials $ 5,031 $ — Work in progress 346 — Finished goods 10,520 13,021 Less inventory reserve (3,734 ) (228 ) Total inventory, net $ 12,163 $ 12,793

Property and Equipment (Tables)

Property and Equipment (Tables)	12 Months Ended
	Dec. 31, 2016
Property, Plant and Equipment [Abstract]
Schedule of Property and Equipment	Property and equipment consists of the following as of December 31: Depreciable 2016 2015 Equipment 5 years $ 4,949 $ 2,070 Furniture, fixtures and tooling 4 - 8 years 3,533 3,429 Computer hardware 3 - 5 years 1,057 1,063 Leasehold improvements 3 - 5 years 1,149 919 Construction in process 605 4,365 11,293 11,846 Less accumulated depreciation (4,404 ) (3,874 ) Property and equipment, net $ 6,889 $ 7,972

Goodwill and Other Intangible32

Goodwill and Other Intangible Assets (Tables)	12 Months Ended
	Dec. 31, 2016
Goodwill and Intangible Assets Disclosure [Abstract]
Schedule of Goodwill	The following table reflects the changes in goodwill for the years ended December 31, 2016 and 2015 : December 31, 2014 $ 184 December 31, 2015 $ 184 Goodwill associated with Lpath, Inc. merger 6,644 December 31, 2016 $ 6,828
Schedule of Intangible Assets	Other intangible assets consist of the following as of December 31: Useful Life 2016 2015 Customer relationships 9 years $ 30,300 $ 30,300 Lap-Band technology 10 years 15,500 15,500 Orbera technology 12 years 4,600 4,600 Trade names 10 years 7,900 7,900 Patents and trademarks 5 years 4,178 2,907 Other 1 - 4 years 1,796 1,460 64,274 62,667 Less accumulated amortization (20,959 ) (13,680 ) $ 43,315 $ 48,987
Schedule of Amortization Expense	Amortization for the next five years is as follows: 2017 $ 7,360 2018 7,233 2019 6,932 2020 6,508 2021 6,209 Thereafter 9,073 Total $ 43,315

Accrued Expenses (Tables)

Accrued Expenses (Tables)	12 Months Ended
	Dec. 31, 2016
Payables and Accruals [Abstract]
Schedule of Accrued Expenses	Accrued expenses consist of the following as of December 31: 2016 2015 Accrued compensation and travel $ 3,040 $ 3,447 Accrued professional service fees 1,521 608 Accrued returns and rebates 366 453 Accrued insurance, property and sales taxes 256 618 Accrued interest 186 155 Deferred rent 152 173 Deferred revenue 88 — Other 1,021 1,092 Total accrued expenses $ 6,630 $ 6,546

Convertible Notes (Tables)

Convertible Notes (Tables)	12 Months Ended
	Dec. 31, 2016
Debt Disclosure [Abstract]
Convertible Notes	2015 Convertible notes $ 22,166 Interest accrued 513 22,679 Discount (2,073 ) Deferred financing costs (108 ) Convertible notes $ 20,498

Long-Term Debt (Tables)

Long-Term Debt (Tables)	12 Months Ended
	Dec. 31, 2016
Debt Disclosure [Abstract]
Schedule of Long-term Debt	Long-term debt consists of the following as of December 31: 2016 2015 Senior secured credit facility $ 39,000 $ 50,000 Payment-in-kind interest 2,046 1,679 Long-term debt 41,046 51,679 Discount on long-term debt (952 ) (1,606 ) Deferred financing costs (667 ) (768 ) Long-term debt $ 39,427 $ 49,305

Stock Option Plans (Tables)

Stock Option Plans (Tables)	12 Months Ended
	Dec. 31, 2016
Disclosure of Compensation Related Costs, Share-based Payments [Abstract]
Schedule of Stock Option Activity	A summary of the stock option activity under the 2006 Plan, 2016 Plan and Lpath Plan (collectively the "Equity Plans") as of December 31, 2016 is presented below. Note that the Company did not account for the Lpath plan until the close of the Merger on December 29, 2016 and the tables below reflect Lpath information only after this date. Options Weighted Average Exercise Price Weighted Average Remaining Contractual Term Aggregate Intrinsic Value (Years) ($000's) Options outstanding, December 31, 2015 972,565 $2.96 7.6 years $— Options granted 235,414 1.99 Options exercised (22,964 ) 2.35 Options forfeited (168,368 ) 1.88 Options outstanding, December 31, 2016 1,016,647 $2.94 7.0 years $9,343 Options vested and expected to vest, December 31, 2016 1,011,863 $2.94 7.0 years $9,343 Options exercisable, December 31, 2016 548,262 $2.79 6.3 years $5,137
Schedule of Fair Value of Stock Options	The fair value of stock option grants has been estimated at the date of grant using the Black-Scholes option pricing model with the following weighted average assumptions for the years ended December 31: 2016 2015 Risk free interest rate 1.4% 1.7% Expected dividend yield —% —% Estimated volatility 57.0% 81.2% Expected life 5.5 years 6.0 years
Schedule of Other Stock Option Information	Additional information regarding options is as follows: 2016 2015 Stock compensation cost $ 381 $ 472 Weighted-average grant date fair value of options granted during the period $ 1.22 $ 2.22 Aggregate intrinsic value of options exercised during the period $ 42 $ 48

Commitments (Tables)

Commitments (Tables)	12 Months Ended
	Dec. 31, 2016
Commitments and Contingencies Disclosure [Abstract]
Schedule of Future Minimum Rental Commitments	At December 31, 2016 , minimum rental commitments under non-cancelable operating leases payable over the next five years are as follows: 2017 $ 1,505 2018 887 2019 569 2020 481 2021 384 Thereafter — Total $ 3,826

Income Taxes (Tables)

Income Taxes (Tables)	12 Months Ended
	Dec. 31, 2016
Income Tax Disclosure [Abstract]
Schedule of Deferred Tax Assets and Liabilities	Significant components of the Company's deferred taxes at December 31 are as follows: 2016 2015 Deferred tax assets: Capitalized transaction costs $ 686 $ 742 Intangible assets 2,794 1,741 Inventory valuation 1,371 173 Research and development credit 2,796 2,522 Foreign timing differences 117 — Unremitted foreign earnings 100 — Other 1,121 1,162 Net operating loss carryforwards 44,087 35,780 53,072 42,120 Deferred tax liabilities: Depreciable assets (288 ) (230 ) (288 ) (230 ) Total net deferred tax assets 52,784 41,890 Less valuation allowance (52,784 ) (41,890 ) Net deferred tax assets (liabilities) $ — $ —
Schedule of Effective Income Tax Rate	The Company's provision for income taxes differs from the expected tax expense amount computed by applying the statutory federal income tax rate of 34% to income before income taxes as a result of the following: 2016 2015 Tax at U.S. statutory rate of 34% $ (13,865 ) $ (9,327 ) State taxes, net of deferred benefit (1,061 ) (628 ) Foreign tax rate differential 422 775 Foreign taxes 91 49 Permanent differences 3,942 269 Contingent purchase price — (1,625 ) Research and development tax credit (240 ) (345 ) Other 204 (18 ) Change in valuation allowance 10,894 10,899 Income tax expense $ 387 $ 49

Net Loss Per Share (Tables)

Net Loss Per Share (Tables)	12 Months Ended
	Dec. 31, 2016
Earnings Per Share [Abstract]
Schedule of Antidilutive Securities Excluded from Computation of Diluted Loss Per Share	Potentially dilutive securities not included in the calculation of diluted net loss per share attributable to common stockholders because to do so would be anti-dilutive are as follows (in common stock equivalent shares): Year Ended December 31 2016 2015 Preferred stock — 6,901,130 Warrants for common and preferred stock 263,856 495,144 Common stock options 1,016,647 972,565 1,280,503 8,368,839

Segment and Geographic Inform40

Segment and Geographic Information (Tables)	12 Months Ended
	Dec. 31, 2016
Segment Reporting [Abstract]
Schedule of Product Sales by Product Group and Geographic Market	Product sales by product group and geographic market, based on the location of the customer, for the periods shown were as follows: Year Ended December 31, 2016 Year Ended December 31, 2015 U.S. OUS Total Revenue % Total Revenue U.S. OUS Total Revenue % Total Revenue Endo-bariatric $ 15,525 $ 16,382 $ 31,907 49.2 % $ 9,119 $ 8,003 $ 17,122 25.3 % Surgical 21,778 10,706 32,484 50.1 % 34,975 12,628 47,603 70.2 % Other 453 24 477 0.7 % 425 2,640 3,065 4.5 % Total revenues $ 37,756 $ 27,112 $ 64,868 100.0 % $ 44,519 $ 23,271 $ 67,790 100.0 % % Total revenue 58.2 % 41.8 % 65.7 % 34.3 %
Schedule of Long-Lived Assets by Geographic Area	The following table represents property and equipment, net based on the physical geographic location of the asset: 2016 2015 United States $ 2,426 $ 3,028 Costa Rica 4,177 4,598 Other 268 346 Total property and equipment, net $ 6,871 $ 7,972

Organization and Business Des41

Organization and Business Description (Details)	Dec. 31, 2016$ / shares	Dec. 29, 2016$ / shares	Dec. 31, 2015$ / shares
Business Acquisition, Equity Interests Issued or Issuable [Line Items]
Common stock, par value (USD per share)	$ 0.001	$ 0.0001	$ 0.001
Reverse stock split, conversion ratio	0.1818
Lpath Inc [Member]
Business Acquisition, Equity Interests Issued or Issuable [Line Items]
Exchange ratio		0.3163
Lpath Inc [Member]
Business Acquisition, Equity Interests Issued or Issuable [Line Items]
Common stock, par value (USD per share)		$ 0.001

Significant Accounting Polici42

Significant Accounting Policies (Narrative) (Details) - USD ($)	12 Months Ended
	Dec. 31, 2016	Dec. 31, 2015
Restricted Cash
Restricted cash	$ 930,000	$ 871,000
Accounts Receivable
Allowance for doubtful accounts	479,000	630,000
Accounts receivable write-offs	482,000	141,000
Fair Value Measurements
Long-term Debt, Fair Value	40,500,000
Goodwill and Other Intangible Assets
Goodwill impairment loss	0	0
Valuation of Long-Lived Assets
Impairment of long-lived assets	0	0
Advertising Expense
Advertising costs	3,484,000	2,319,000
Medical Devices [Member]
Medical Device Excise Tax
Excise tax	$ 0	$ 754,000

Significant Accounting Polici43

Significant Accounting Policies (Fair Value Measurements) (Details) - Warrant [Member] - USD ($) $ in Thousands	Dec. 31, 2016	Dec. 31, 2015
Carrying Value [Member]
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]
Warrants classified as a liability	$ 0	$ 2,912
Fair Value [Member] | Level 3 [Member]
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]
Warrants classified as a liability	$ 0	$ 2,912

Acquisitions (Lpath) (Details)

Acquisitions (Lpath) (Details) - USD ($)	Dec. 29, 2016	Dec. 31, 2016	Dec. 31, 2015	Dec. 31, 2014
Business Acquisition [Line Items]
Percentage of fully diluted stock	95.90%
Goodwill		$ 6,828,000	$ 184,000	$ 184,000
Pro Forma Information
Interest expense		18,168,000	10,036,000
Lpath [Member]
Business Acquisition [Line Items]
Percentage of fully diluted stock	4.10%
Total purchase price	$ 7,087,000
Cash	200,000
Other assets	519,000
Assumed liabilities	(276,000)
Fair value of net assets	443,000
Goodwill	6,644,000
Total purchase consideration	7,087,000
Pro Forma Information
Pro form combined revenues		65,163	69,390
Pro forma combined net loss		$ (33,269)	$ (34,521)
Pro forma combined earnings per share (USD per share)		$ (3.11)	$ (4.23)
Lpath [Member] | General and Administrative Expense [Member]
Business Acquisition [Line Items]
Transaction costs	$ 3,640,000
Acquisition-related Costs [Member] | Lpath [Member]
Business Acquisition [Line Items]
Transaction costs		$ 5,140,000
Pro Forma Information
Interest expense		$ 13,258,000	$ 2,920,000

Acquisitions (Starhealth) (Deta

Acquisitions (Starhealth) (Details) - Starhealth [Member] $ in Thousands	Jun. 03, 2015USD ($)
Business Acquisition [Line Items]
Amount paid for shares	$ 144
Business Licenses [Member]
Business Acquisition [Line Items]
Intangible assets acquired	$ 144
Amortization period	1 year

Acquisitions (Allergan) (Detail

Acquisitions (Allergan) (Details) - USD ($) $ in Thousands	May 26, 2016	Dec. 02, 2015	Dec. 02, 2013	Dec. 31, 2016	Dec. 31, 2015
Business Acquisition [Line Items]
Business combination with Lpath, Inc.				$ 7,087
Research and development expense				7,805	$ 9,558
Asset Purchase Agreement [Member]
Business Acquisition [Line Items]
Payments for Allergan			$ 62,460
Threshold period			3 years
Inventory purchases				$ 7,667	13,555
Asset Purchase Agreement [Member] | Lap-Band [Member]
Business Acquisition [Line Items]
Manufacturing fee percent		115.00%
Asset Purchase Agreement [Member] | Orbera [Member]
Business Acquisition [Line Items]
Payments for Allergan	$ 5,000
Asset Purchase Agreement [Member] | Lap-Band and Orbera [Member]
Business Acquisition [Line Items]
Licenses fee revenue					2,624
Research and development expense					$ 1,240
Asset Purchase Agreement [Member] | Series C Preferred Stock [Member]
Business Acquisition [Line Items]
Business combination with Lpath, Inc.			$ 15,000

Concentrations (Details)

Concentrations (Details) $ in Thousands	Dec. 31, 2016USD ($)bank
Risks and Uncertainties [Abstract]
Number of banks | bank	3
Cash and cash equivalents and restricted cash | $	$ 20,041

Inventory (Details)

Inventory (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2016	Dec. 31, 2015
Inventory Disclosure [Abstract]
Raw materials	$ 5,031	$ 0
Work in progress	346	0
Finished goods	10,520	13,021
Less inventory reserve	(3,734)	(228)
Total inventory, net	12,163	12,793
Inventory [Line Items]
Change in inventory reserve	3,750	$ (54)
Raw Materials [Member]
Inventory [Line Items]
Change in inventory reserve	1,226
Finished Goods [Member]
Inventory [Line Items]
Change in inventory reserve	$ 2,524

Property and Equipment (Details

Property and Equipment (Details) - USD ($)	12 Months Ended
	Dec. 31, 2016	Dec. 31, 2015
Property, Plant and Equipment [Line Items]
Property and equipment, gross	$ 11,293,000	$ 11,846,000
Less accumulated depreciation	(4,404,000)	(3,874,000)
Property and equipment, net	6,889,000	7,972,000
Depreciation expense	1,862,000	1,225,000
Impairment charge	0	0
Capitalized interest	109,000	269,000
Disposal of property and equipment	1,270,000
Equipment [Member]
Property, Plant and Equipment [Line Items]
Property and equipment, gross	$ 4,949,000	2,070,000
Depreciable lives	5 years
Furniture, Fixtures and Tooling [Member]
Property, Plant and Equipment [Line Items]
Property and equipment, gross	$ 3,533,000	3,429,000
Furniture, Fixtures and Tooling [Member] | Minimum [Member]
Property, Plant and Equipment [Line Items]
Depreciable lives	4 years
Furniture, Fixtures and Tooling [Member] | Maximum [Member]
Property, Plant and Equipment [Line Items]
Depreciable lives	8 years
Computer Hardware [Member]
Property, Plant and Equipment [Line Items]
Property and equipment, gross	$ 1,057,000	1,063,000
Computer Hardware [Member] | Minimum [Member]
Property, Plant and Equipment [Line Items]
Depreciable lives	3 years
Computer Hardware [Member] | Maximum [Member]
Property, Plant and Equipment [Line Items]
Depreciable lives	5 years
Leasehold Improvements [Member]
Property, Plant and Equipment [Line Items]
Property and equipment, gross	$ 1,149,000	919,000
Leasehold Improvements [Member] | Minimum [Member]
Property, Plant and Equipment [Line Items]
Depreciable lives	3 years
Leasehold Improvements [Member] | Maximum [Member]
Property, Plant and Equipment [Line Items]
Depreciable lives	5 years
Construction in Progress [Member]
Property, Plant and Equipment [Line Items]
Property and equipment, gross	$ 605,000	$ 4,365,000

Goodwill and Other Intangible50

Goodwill and Other Intangible Assets (Goodwill) (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2016	Dec. 31, 2014
Business Combinations [Abstract]
Goodwill	$ 184	$ 184
Goodwill
Beginning balance	184
Acquisitions	6,644
Ending balance	$ 6,828

Goodwill and Other Intangible51

Goodwill and Other Intangible Assets (Other Intangible Assets) (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2016	Dec. 31, 2015
Finite-Lived Intangible Assets [Line Items]
Intangible assets, gross	$ 64,274	$ 62,667
Less accumulated amortization	(20,959)	(13,680)
Total	43,315	48,987
Amortization of intangible assets	$ 7,230	6,835
Lap-Band [Member]
Finite-Lived Intangible Assets [Line Items]
Useful life	10 years
Intangible assets, gross	$ 15,500	15,500
Orbera [Member]
Finite-Lived Intangible Assets [Line Items]
Useful life	12 years
Intangible assets, gross	$ 4,600	4,600
Customer Relationships [Member]
Finite-Lived Intangible Assets [Line Items]
Useful life	9 years
Intangible assets, gross	$ 30,300	30,300
Trade Names [Member]
Finite-Lived Intangible Assets [Line Items]
Useful life	10 years
Intangible assets, gross	$ 7,900	7,900
Patents and Trademarks [Member]
Finite-Lived Intangible Assets [Line Items]
Useful life	5 years
Intangible assets, gross	$ 4,178	2,907
Cost incurred to extend and renew patents and trademarks	1,271	1,256
Other [Member]
Finite-Lived Intangible Assets [Line Items]
Intangible assets, gross	$ 1,796	$ 1,460
Other [Member] | Minimum [Member]
Finite-Lived Intangible Assets [Line Items]
Useful life	1 year
Other [Member] | Maximum [Member]
Finite-Lived Intangible Assets [Line Items]
Useful life	4 years

Goodwill and Other Intangible52

Goodwill and Other Intangible Assets (Amortization Expense) (Details) - USD ($) $ in Thousands	Dec. 31, 2016	Dec. 31, 2015
Goodwill and Intangible Assets Disclosure [Abstract]
2,017	$ 7,360
2,018	7,233
2,019	6,932
2,020	6,508
2,021	6,209
Thereafter	9,073
Total	$ 43,315	$ 48,987

Accrued Expenses (Details)

Accrued Expenses (Details) - USD ($) $ in Thousands	Dec. 31, 2016	Dec. 31, 2015
Payables and Accruals [Abstract]
Accrued compensation and travel	$ 3,040	$ 3,447
Accrued professional service fees	1,521	608
Accrued returns and rebates	366	453
Accrued insurance, property and sales taxes	256	618
Accrued interest	186	155
Deferred rent	152	173
Deferred revenue	88	0
Other	1,021	1,092
Total accrued expenses	$ 6,630	$ 6,546

Convertible Notes (Details)

Convertible Notes (Details) $ / shares in Units, $ in Thousands	Dec. 29, 2016USD ($)$ / shares	Nov. 30, 2015USD ($)	Dec. 31, 2016USD ($)shares	Dec. 31, 2015USD ($)	Jul. 29, 2016$ / shares
Debt Instrument [Line Items]
Proceeds from the issuance of convertible notes			$ 0	$ 22,166
Convertible Debt [Member]
Debt Instrument [Line Items]
Proceeds from the issuance of convertible notes		$ 22,166
Interest rate		6.00%
Interest accrued			1,326	513
Conversion price (USD per share) | $ / shares	$ 1.6361
Beneficial conversion feature	$ 8,678	$ 3,325
Amortization of discount			$ 2,073	$ 1,252
Percentage of outstanding principal	1.50
Shares converted into common stock | shares			1,269,900
Convertible Debt [Member] | Minimum [Member]
Debt Instrument [Line Items]
Conversion ratio, conversion due to qualifying event		115.00%
Convertible Debt [Member] | Maximum [Member]
Debt Instrument [Line Items]
Conversion ratio, conversion due to qualifying event		150.00%
Convertible Debt [Member] | Series C Preferred Stock [Member]
Debt Instrument [Line Items]
Conversion ratio, voluntary conversion		115.00%
Conversion price (USD per share) | $ / shares					$ 1.2223

Convertible Notes (Schedule of

Convertible Notes (Schedule of Convertible Notes) (Details) - USD ($) $ in Thousands	Dec. 31, 2016	Dec. 31, 2015
Debt Instrument [Line Items]
Long-term debt, gross	$ 41,046	$ 51,679
Discount on long-term debt	(952)	(1,606)
Deferred financing costs	(667)	(768)
Long-term debt	39,427	49,305
Convertible Debt [Member]
Debt Instrument [Line Items]
Convertible notes		22,166
Interest accrued	$ 1,326	513
Long-term debt, gross		22,679
Discount on long-term debt		(2,073)
Deferred financing costs		(108)
Long-term debt		$ 20,498

Long-Term Debt (Schedule of Lon

Long-Term Debt (Schedule of Long-term Debt) (Details) - USD ($) $ in Thousands	Dec. 31, 2016	Dec. 31, 2015
Debt Instrument [Line Items]
Long-term debt, gross	$ 41,046	$ 51,679
Discount on long-term debt	(952)	(1,606)
Deferred financing costs	(667)	(768)
Long-term debt	39,427	49,305
Payment in Kind Interest [Member]
Debt Instrument [Line Items]
Long-term debt, gross	2,046	1,679
Line of Credit [Member] | Secured Debt [Member] | Credit Facility [Member]
Debt Instrument [Line Items]
Long-term debt, gross	$ 39,000	$ 50,000

Long-Term Debt (Senior Secured

Long-Term Debt (Senior Secured Credit Facility) (Details)	Dec. 29, 2016USD ($)	Oct. 10, 2016USD ($)$ / sharesshares	Mar. 15, 2016	Feb. 28, 2015USD ($)	Dec. 31, 2016USD ($)	Dec. 31, 2015USD ($)	Mar. 31, 2016USD ($)	Feb. 27, 2015USD ($)$ / sharesshares	Nov. 30, 2013
Debt Instrument [Line Items]
Proceeds from long-term debt					$ 0	$ 50,000,000
Change in fair value of warrant liability					1,163,000	49,000
Notes Payable [Member] | Consortium Loan [Member]
Debt Instrument [Line Items]
Interest rate									8.25%
Repayments of debt						39,500,000
Unamortized deferred financing costs				$ 641,000
Line of Credit [Member] | Secured Debt [Member] | Credit Facility [Member]
Debt Instrument [Line Items]
Maximum borrowing capacity								$ 50,000,000
Interest rate								10.50%
Cash interest quarterly								7.00%
Payment-in-kind interest								3.50%
Percent of outstanding due at end of loan			2.00%
Repayments of debt	$ 11,000,000
Unamortized deferred financing costs					127,000
Discount on long-term debt					269,000
Covenant, minimum cash on hand						5,000,000	$ 10,000,000
Line of Credit [Member] | Secured Debt [Member] | Credit Facility [Member] | Warrant [Member] | Common Stock [Member]
Debt Instrument [Line Items]
Issued warrants to purchase shares, number of shares | shares								163,915
Exercise price (USD per share) | $ / shares								$ 21.29
Fair value of warrants issued								$ 1,951,000
Change in fair value of warrant liability					$ 641,000	$ 24,000
Line of Credit [Member] | Secured Debt [Member] | Credit Facility Amendment [Member]
Debt Instrument [Line Items]
Minimum cash requirement		$ 8,000,000
Line of Credit [Member] | Secured Debt [Member] | Credit Facility Amendment [Member] | Minimum [Member]
Debt Instrument [Line Items]
Quarterly revenue requirement		$ 15,700
Minimum debt to revenue ratio		0.80
Line of Credit [Member] | Secured Debt [Member] | Credit Facility Amendment [Member] | Maximum [Member]
Debt Instrument [Line Items]
Quarterly revenue requirement		$ 25,000
Minimum debt to revenue ratio		0.40
Line of Credit [Member] | Secured Debt [Member] | Credit Facility Amendment [Member] | Warrant [Member] | Common Stock [Member]
Debt Instrument [Line Items]
Issued warrants to purchase shares, number of shares | shares		163,915
Exercise price (USD per share) | $ / shares		$ 21.29
Line of Credit [Member] | Payment in Kind Interest [Member] | Credit Facility [Member]
Debt Instrument [Line Items]
Repayments of debt	$ 770,000

Long-Term Debt (Note with a Con

Long-Term Debt (Note with a Consortium of Lenders) (Details) - USD ($)	Feb. 28, 2015	Nov. 30, 2013	Dec. 31, 2016	Dec. 31, 2015
Debt Instrument [Line Items]
Change in fair value of warrant liability			$ (1,163,000)	$ (49,000)
Common Stock [Member]
Debt Instrument [Line Items]
Shares converted into common stock			7,326,643
Notes Payable [Member] | Consortium Loan [Member]
Debt Instrument [Line Items]
Face amount of debt		$ 50,000,000
Interest rate		8.25%
Debt term		60 months
Prepayment penalty	$ 1,795,000
Unamortized deferred financing costs	$ 641,000
Notes Payable [Member] | Consortium Loan [Member] | Other Noncurrent Assets [Member]
Debt Instrument [Line Items]
Commitment fees		$ 750,000
Legal fees		$ 241,000
Notes Payable [Member] | Consortium Loan [Member] | Series C Preferred Stock [Member] | Warrant [Member]
Debt Instrument [Line Items]
Issued warrants to purchase shares, number of shares		70,580
Exercise price (USD per share)		$ 21.29
Fair value of warrants issued		$ 1,142,000
Change in fair value of warrant liability			$ 522,000	$ 25,000
Notes Payable [Member] | Consortium Loan [Member] | Common Stock [Member] | Warrant [Member]
Debt Instrument [Line Items]
Shares converted into common stock			44,027

Stockholders' Equity (Authorize

Stockholders' Equity (Authorized Stock) (Details) - $ / shares	12 Months Ended
	Dec. 31, 2016	Dec. 29, 2016	Dec. 28, 2016	Dec. 31, 2015
Class of Stock [Line Items]
Preferred and common stock, shares authorized	115,000,000
Common stock, shares authorized	100,000,000			100,000,000
Common stock, par value (USD per share)	$ 0.001	$ 0.0001		$ 0.001
Preferred stock, shares authorized	15,000,000		107,574,742
Preferred stock, par value (USD per share)	$ 0.001
Annual dividend rate	8.00%
Preferred stock, shares outstanding		0
Series A Convertible Preferred Stock [Member]
Class of Stock [Line Items]
Preferred stock, shares authorized			10,006,345
Preferred stock, shares outstanding				9,588,891
Series B Convertible Preferred Stock [Member]
Class of Stock [Line Items]
Preferred stock, shares authorized			45,431,126
Preferred stock, shares outstanding				45,406,582
Series C Convertible Preferred Stock [Member]
Class of Stock [Line Items]
Preferred stock, shares authorized			52,137,271
Preferred stock, shares outstanding				37,617,334

Stockholders' Equity (Merger) (

Stockholders' Equity (Merger) (Details) $ in Thousands	Dec. 31, 2016USD ($)	Dec. 31, 2016USD ($)shares	Dec. 29, 2016shares
Class of Stock [Line Items]
Accumulated dividends | $	$ 42,507	$ 42,507
Reverse stock split, conversion ratio	0.1818
Preferred stock, shares outstanding | shares			0
Shares sold, amount | $		$ 29,000
Common Stock [Member]
Class of Stock [Line Items]
Conversion of convertible securities ratio		1
Shares converted into common stock | shares		7,326,643
Shares sold | shares		1,019,441
Shares sold, amount | $		$ 29,000

Stockholders' Equity (Warrants)

Stockholders' Equity (Warrants) (Details) - $ / shares	12 Months Ended
	Dec. 31, 2016	Dec. 28, 2016	Dec. 29, 2016
Common Stock [Member]
Class of Warrant or Right [Line Items]
Shares converted into common stock	7,326,643
Warrant [Member] | Lpath Inc [Member]
Class of Warrant or Right [Line Items]
Issued warrants to purchase shares, number of shares	59,537
Exercise price (USD per share)	$ 324.08
Warrant [Member] | Common Stock [Member] | Lpath Inc [Member]
Class of Warrant or Right [Line Items]
Issued warrants to purchase shares, number of shares			40,456
Exercise price (USD per share)			$ 13.70
Preferred Stock Warrants [Member] | Common Stock [Member]
Class of Warrant or Right [Line Items]
Shares converted into common stock		15,866
Common Stock Warrants [Member] | Common Stock [Member]
Class of Warrant or Right [Line Items]
Shares converted into common stock		234,545

Stock Option Plans (Plans) (Det

Stock Option Plans (Plans) (Details) - shares	5 Months Ended	12 Months Ended
	May 31, 2016	Dec. 31, 2016
2006 Plan [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Percentage of fair value	100.00%
Maximum term of options granted	10 years
2006 Plan [Member] | Maximum [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Vesting period	5 years
2016 Plan [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Percentage of fair value		100.00%
Maximum term of options granted		10 years
Common stock reserved for issuance		21,319,756
2016 Plan [Member] | Maximum [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Vesting period		5 years
Lpath Plan [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Maximum term of options granted		10 years
Options expired		3,182
Lpath Plan [Member] | Minimum [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Vesting period		0 years
Lpath Plan [Member] | Maximum [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Vesting period		5 years
Lpath Plan [Member] | Incentive Stock Options [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Percentage of fair value		100.00%
Lpath Plan [Member] | Nonqualified Options [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Percentage of fair value		85.00%

Stock Option Plans (Stock Optio

Stock Option Plans (Stock Option Activity) (Details) - Equity Plans [Member] - Stock Option [Member] - USD ($) $ / shares in Units, $ in Thousands	12 Months Ended
	Dec. 31, 2016	Dec. 31, 2015
Options
Options outstanding, beginning balance (in shares)	972,565
Options granted (in shares)	235,414
Options exercised (in shares)	(22,964)
Options forfeited (in shares)	(168,368)
Options outstanding, ending balance (in shares)	1,016,647	972,565
Options vested and expected to vest, December 31, 2016 (in shares)	1,011,863
Options exercisable, December 31, 2016 (in shares)	548,262
Weighted Average Exercise Price
Weighted average exercise price, beginning balance (in USD per share)	$ 2.96
Options granted (in USD per share)	1.99
Options exercised (in USD per share)	2.35
Options forfeited (in USD per share)	1.88
Weighted average exercise price, ending balance (in USD per share)	2.94	$ 2.96
Options vested and expected to vest, December 31, 2016 (in USD per share)	2.94
Options exercisable, December 31, 2016 (in USD per share)	$ 2.79
Weighted Average Remaining Contractual Term
Weighted average remaining contractual term	7 years 1 day	7 years 7 months 6 days
Options vested and expected to vest, December 31, 2016	7 years 18 days
Options exercisable, December 31, 2016	6 years 3 months 18 days
Aggregate Intrinsic Value
Aggregate intrinsic value	$ 9,343	$ 0
Options vested and expected to vest, December 31, 2016	9,343
Options exercisable, December 31, 2016	$ 5,137

Stock Option Plans (Fair Value

Stock Option Plans (Fair Value of Stock Options) (Details) - Stock Option [Member]	12 Months Ended
	Dec. 31, 2016	Dec. 31, 2015
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Risk free interest rate	1.40%	1.70%
Expected dividend yield	0.00%	0.00%
Estimated volatility	57.00%	81.20%
Expected life	5 years 5 months 18 days	6 years

Stock Option Plans (Additional

Stock Option Plans (Additional Information, Stock Options) (Details) - USD ($) $ / shares in Units, $ in Thousands	12 Months Ended
	Dec. 31, 2016	Dec. 31, 2015
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Stock based compensation	$ 381	$ 472
Unrecognized compensation expense related to unvested options	$ 567
Remaining amortization period, less then	4 years
Stock Option [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Stock based compensation	$ 381	$ 472
Weighted-average grant date fair value of options granted during the period (USD per share)	$ 1.22	$ 2.22
Aggregate intrinsic value of options exercised during the period	$ 42	$ 48
Performance Shares [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Options granted in period	139,513

Commitments (Lease Commitments)

Commitments (Lease Commitments) (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2016	Dec. 31, 2015
Commitments and Contingencies Disclosure [Abstract]
Lease expense	$ 1,120	$ 930
Minimum Rental Commitments
2,017	1,505
2,018	887
2,019	569
2,020	481
2,021	384
Thereafter	0
Total	$ 3,826

Commitments (Employment Agreeme

Commitments (Employment Agreements) (Details) - Executive Officer [Member]	12 Months Ended
	Dec. 31, 2016
Other Commitments [Line Items]
Period following change in control	12 months
Minimum [Member]
Other Commitments [Line Items]
Period for salary and benefits payment	3 months
Maximum [Member]
Other Commitments [Line Items]
Period for salary and benefits payment	12 months

Defined Contribution Plan (Deta

Defined Contribution Plan (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2016	Dec. 31, 2015
Compensation and Retirement Disclosure [Abstract]
Cost of defined contribution plan	$ 553	$ 555

Income Taxes (Narrative) (Detai

Income Taxes (Narrative) (Details) - USD ($)	12 Months Ended
	Dec. 31, 2016	Dec. 31, 2015
Operating Loss Carryforwards [Line Items]
Income tax expense	$ 387,000	$ 49,000
Valuation allowance, increase	10,894,000
Unrecognized tax benefits	0
Accrued interest	0
Tax penalties	$ 0
Statutory federal income tax rate	34.00%
Domestic Tax Authority [Member]
Operating Loss Carryforwards [Line Items]
Operating loss carryforwards	$ 123,335,000
State and Local Jurisdiction [Member]
Operating Loss Carryforwards [Line Items]
Operating loss carryforwards	43,330,000
Foreign Tax Authority [Member]
Operating Loss Carryforwards [Line Items]
Operating loss carryforwards	4,120,000
Operating loss, indefinite carryforward	0
Operating loss carryforwards, subject to expiration	$ 4,120,000

Income Taxes (Deferred Tax Asse

Income Taxes (Deferred Tax Assets Liabilities) (Details) - USD ($) $ in Thousands	Dec. 31, 2016	Dec. 31, 2015
Deferred tax assets:
Capitalized transaction costs	$ 686	$ 742
Intangible assets	2,794	1,741
Inventory valuation	1,371	173
Research and development credit	2,796	2,522
Foreign timing differences	117	0
Unremitted foreign earnings	100	0
Other	1,121	1,162
Net operating loss carryforwards	44,087	35,780
Deferred tax assets, gross	53,072	42,120
Deferred tax liabilities:
Depreciable assets	(288)	(230)
Total deferred tax liabilities	(288)	(230)
Total net deferred tax assets	52,784	41,890
Less valuation allowance	(52,784)	(41,890)
Net deferred tax assets (liabilities)	$ 0	$ 0

Income Taxes (Effective Income

Income Taxes (Effective Income Tax Rate) (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2016	Dec. 31, 2015
Income Tax Disclosure [Abstract]
Statutory federal income tax rate	34.00%
Tax at U.S. statutory rate of 34%	$ (13,865)	$ (9,327)
State taxes, net of deferred benefit	(1,061)	(628)
Foreign tax rate differential	422	775
Foreign taxes	91	49
Permanent differences	3,942	269
Contingent purchase price	0	(1,625)
Research and development tax credit	(240)	(345)
Other	204	(18)
Change in valuation allowance	10,894	10,899
Income tax expense	$ 387	$ 49

Net Loss Per Share (Details)

Net Loss Per Share (Details) - shares	12 Months Ended
	Dec. 31, 2016	Dec. 31, 2015
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Antidilutive securities excluded from computation of diluted loss per share	1,280,503	8,368,839
Preferred Stock [Member]
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Antidilutive securities excluded from computation of diluted loss per share	0	6,901,130
Warrants for common and preferred stock [Member]
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Antidilutive securities excluded from computation of diluted loss per share	263,856	495,144
Common stock options [Member]
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Antidilutive securities excluded from computation of diluted loss per share	1,016,647	972,565

Related Party Transactions (Det

Related Party Transactions (Details) - Allergan [Member] - Affiliated Entity [Member] - USD ($) $ in Thousands	Dec. 31, 2016	Dec. 31, 2015
Related Party Transaction [Line Items]
Shares held by related party	70,580
Transitional Services [Member]
Related Party Transaction [Line Items]
Payable to related parties	$ 1,259	$ 1,205
Inventory Purchases [Member]
Related Party Transaction [Line Items]
Payable to related parties	$ 7,246	$ 3,750

Liquidity and Capital Resourc74

Liquidity and Capital Resources (Details) - USD ($) $ in Thousands	Dec. 31, 2016	Dec. 31, 2015
Debt Disclosure [Abstract]
Accumulated deficit	$ (149,729)	$ (108,562)

Segment and Geographic Inform75

Segment and Geographic Information (Segment Information) (Details) $ in Thousands	12 Months Ended
	Dec. 31, 2016USD ($)segment	Dec. 31, 2015USD ($)
Revenue, Major Customer [Line Items]
Number of reportable segments | segment	1
Revenues	$ 64,868	$ 67,790
United States [Member]
Revenue, Major Customer [Line Items]
Revenues	37,756	44,519
Other countries [Member]
Revenue, Major Customer [Line Items]
Revenues	$ 27,112	$ 23,271
Segment Revenue [Member] | Product Risk [Member]
Revenue, Major Customer [Line Items]
Percentage of total revenue	100.00%	100.00%
Segment Revenue [Member] | Product Risk [Member] | United States [Member]
Revenue, Major Customer [Line Items]
Percentage of total revenue	58.20%	65.70%
Segment Revenue [Member] | Product Risk [Member] | Other countries [Member]
Revenue, Major Customer [Line Items]
Percentage of total revenue	41.80%	34.30%
Endo-Bariatric [Member]
Revenue, Major Customer [Line Items]
Revenues	$ 31,907	$ 17,122
Endo-Bariatric [Member] | United States [Member]
Revenue, Major Customer [Line Items]
Revenues	15,525	9,119
Endo-Bariatric [Member] | Other countries [Member]
Revenue, Major Customer [Line Items]
Revenues	$ 16,382	$ 8,003
Endo-Bariatric [Member] | Segment Revenue [Member] | Product Risk [Member]
Revenue, Major Customer [Line Items]
Percentage of total revenue	49.20%	25.30%
Surgical [Member]
Revenue, Major Customer [Line Items]
Revenues	$ 32,484	$ 47,603
Surgical [Member] | United States [Member]
Revenue, Major Customer [Line Items]
Revenues	21,778	34,975
Surgical [Member] | Other countries [Member]
Revenue, Major Customer [Line Items]
Revenues	$ 10,706	$ 12,628
Surgical [Member] | Segment Revenue [Member] | Product Risk [Member]
Revenue, Major Customer [Line Items]
Percentage of total revenue	50.10%	70.20%
Other [Member]
Revenue, Major Customer [Line Items]
Revenues	$ 477	$ 3,065
Other [Member] | United States [Member]
Revenue, Major Customer [Line Items]
Revenues	453	425
Other [Member] | Other countries [Member]
Revenue, Major Customer [Line Items]
Revenues	$ 24	$ 2,640
Other [Member] | Segment Revenue [Member] | Product Risk [Member]
Revenue, Major Customer [Line Items]
Percentage of total revenue	0.70%	4.50%

Segment and Geographic Inform76

Segment and Geographic Information (Long-Lived Assets by Geographic Area) (Details) - USD ($) $ in Thousands	Dec. 31, 2016	Dec. 31, 2015
Revenues from External Customers and Long-Lived Assets [Line Items]
Total property and equipment, net	$ 6,871	$ 7,972
United States [Member]
Revenues from External Customers and Long-Lived Assets [Line Items]
Total property and equipment, net	2,426	3,028
Costa Rica [Member]
Revenues from External Customers and Long-Lived Assets [Line Items]
Total property and equipment, net	4,177	4,598
Other countries [Member]
Revenues from External Customers and Long-Lived Assets [Line Items]
Total property and equipment, net	$ 268	$ 346

Subsequent Events (Details)

Subsequent Events (Details) - Secured Debt [Member] - Credit Facility Fifth Amendment [Member] - Line of Credit [Member]	Mar. 07, 2017USD ($)	Dec. 31, 2016USD ($)
Subsequent Event [Line Items]
Covenant, minimum cash on hand		$ 0
Quarterly revenue requirement		$ 13,000,000
Minimum debt to revenue ratio		0.65
Subsequent Event [Member]
Subsequent Event [Line Items]
Covenant, minimum cash on hand	$ 8,000,000
Quarterly revenue requirement	$ 18,000,000
Minimum debt to revenue ratio	0.60
Repayments of debt	$ 7,000,000
Increase in quarterly revenue	$ 1,000,000
Scenario, Forecast [Member] | Subsequent Event [Member]
Subsequent Event [Line Items]
Minimum debt to revenue ratio	0.25

Uncategorized Items - lptn-2016

Label	Element	Value
Additional Paid-in Capital [Member] | Convertible Debt [Member]
Adjustments to Additional Paid in Capital, Convertible Debt with Conversion Feature	us-gaap_AdjustmentsToAdditionalPaidInCapitalConvertibleDebtWithConversionFeature	$ 8,678,000